

Bibliographie CANNABIDIOL

Dr Christian Sueur, GRECC, avril 2020.

Voir aussi :

- Bibliographie Cannabidiol et psychiatrie (CBD anxiolytique, "antipsychotique" et "antidépresseur", CBD et addictions)
<https://www.grecc.org/publications/bibliographies/bibliographie-cannabis-et-cannabinoides-en-psychiatrie-docteur-christian-sueur-grecc-novembre-2019/>
- Bibliographie Cannabinoides et PTSD - Troubles psychotraumatiques
<https://www.grecc.org/publications/bibliographies/bibliographie-cannabinoides-et-ptsd-docteur-christian-sueur-grecc-2019/>
- Bibliographie CBD et épilepsie
<https://www.grecc.org/publications/bibliographies/bibliographie-cannabinoides-et-epilepsie-docteur-christian-sueur-grecc-decembre-2019/>
- Bibliographie CBD et neuroprotection
<https://www.grecc.org/publications/bibliographies/bibliographie-cannabinoides-et-neuroprotection/>
- Bibliographie CBD et maladies neurodégénératives
<https://www.grecc.org/publications/bibliographies/bibliographie-cannabinoides-et-maladies-neurodegeneratives/>
- Bibliographie CBD et neurologie
<https://www.grecc.org/publications/bibliographies/bibliographie-cannabis-et-cannabinoides-en-neurologie-docteur-christian-sueur-grecc-mars-2020-2/>
- Bibliographie CBD et douleurs neuropathiques
<https://www.grecc.org/publications/bibliographies/bibliographie-cannabinoides-et-douleurs-neuropathiques/>
- Bibliographie Interactions et antagonisme CBD - THC
<https://www.grecc.org/publications/bibliographies/bibliographie-interactions-et-antagonisme-thc-cbd-docteur-christian-sueur-grecc-novembre-2019/>
- Bibliographie Cannabinoides et Autisme (TSA, TED, psychoses...)
<https://www.grecc.org/publications/bibliographies/bibliographie-cannabinoides-et-tsa-ted-psychoses-infantiles-dr-christian-sueur-grecc-version-actualisee-juin-2019/>

1. ADAMS R., HUNT M., CLARK J.H. : Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp, *Journal of the American Chemical Society*, 1940, 62, 196-200.
2. AGUIRRE-VELASQUEZ C.G. : Report from a Survey of Parents Regarding the Use of Cannabidiol (*Medicinal cannabis*) in Mexican Children with refractory Epilepsy, *Hindawi, Neurology Research International*, 2017, ID 2985729, 5 p.

3. AKGÜN K., ESSNER U., SEYDEL C., ZIEMSSEN T. : Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol : Cannabidiol Oromucosal Spray : A Systematic Review of Observational Studies, *Journal of Central Nervous System Disease*, 2019, 11, 1-18.
Doi : 10.1177/1179573519831997
4. ALMEIDA V., LEVIN R., PERES F.F., NIIGAKI S.T., CALZAVARA M.B., ZUARDI A.W., HALLAK J.E., CRIPPA J.A., ABILIO V.C. : Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test, *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 2013, 41, 30-35.
Doi : 10.1016/j.pnpbp.2012.10.024
5. AMES F.R., CRIDLAND S. : Anticonvulsant effect of cannabidiol, *South Africa Medical Journal*, 1986, 69, 1, 14.
6. ANDERSON P. : Positive Topline Results with Cannabidiol (Epidiolex) in Dravet Syndrome, [www.medscape.com/viewarticle/860357 print](http://www.medscape.com/viewarticle/860357), 2016
7. ANDERSON C.L., EVANS V.F., DeMARSE T.B., FEBO M., JOHNSON C.R., CARNEY P.R. : Cannabidiol for the Treatment of Drug-Resistant Epilepsy in Children : Current State of Research, *Journal of Pediatric Neurology*, 2017, 15, 143-150.
Doi : 10.1055/s-0037-1598109
8. ANDRE C.M., HAUSMAN J.F., GUERRERO G. : Cannabis sativa : The Plant of the Thousand and One Molecules, *Frontiers in Plant Science*, 2016, 7, 19.
Doi : 10.3389/fpls.2016.00019
9. ANSM : Cannabis thérapeutique en France : Programme de travail du CSST – Point d'information, 10/10/2018,
<https://ansm.sante.fr/S-informer/Actualite/Cannabis-therapeutique-en-France-programme-de-travail-du-CSST-point-d-Information>
10. ARAN A., CASSUTO H., LUBOTZKY A., WATTAD N., HAZAN E. : Brief Report : Cannabidiol-Rich cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems - A Retrospective Feasibility Study, *Journal of Autism and Developmental Disorders*, 2018, Oct 31.
Doi : 10.1007/s10803-018-3808-2
11. ARKELL T.R., LINTZERIS N., KEVIN R.C., RAMAEKERS J.G., VANDREY R., IRWIN C., HABER P.S., McGREGOR I.S. : Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition, *Psychopharmacology*, 2019, 12 p.
Doi : 10.1007/s00213-019-05246-8
12. ARRUDA L., PAZOS M.R., MOHAMMED N., ESCRIBANO N., LAFUENTE H., SANTOS M., ALVAREZ-DIAZ F.J., HIND W., MARTINEZ-ORGADO J. : Cannabidiol reduces lung injury induced by hypoxicischemic brain damage in newborn piglets, *Pediatric Research*, 2017, 82, (1), 79-86.
13. ATSMON J., HEFFETZ D., DEUTSCH L. et al. : Single-dose pharmacokinetics of oral cannabidiol following administration of PTL101 : a new formulation based on gelatin matrix pellets technology, *Clinical Pharmacology in Drug Development*, 2018, 7, (7), 751-758.
Doi : 10.1002/cptd.408
14. AVIELLO G., ROMANO B., BORRELLI F., CAPASSO R., GALLO L., PISCITELLI F., Di MARZO V., IZZO A.A. : Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer, *Journal of Molecular Medicine (Berl)*, 2012, 90, (8), 925-934.

15. AVRAHAM Y., GRIGORIADIS N., POUTAHIDIS T., VOROBIEV L., MAGEN I., ILAN Y., MECHOULAM R., BERRY E. : Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice, *British Journal of Pharmacology*, 2011, 162, (7), 1650-1658.
16. BARNES G., SULLIVAN J., SEARS L., et al. : Safety and tolerability of GWP42006 (CBDV) in subjects with drug resistant epilepsy and autism, Presented at : *American Epilepsy Society Annual Meeting*, New Orleans, LA, November 30-December 4, 2018, Poster 3.288.
17. BATALLA A., JANSSEN H., GANGADIN S.S., BOSSONG M.G. : The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review, *Journal of Clinical Medicine*, 2019, 8, 1058.
Doi : 10.3390/jcm8071058
18. BEALE C., BROYD S.J., CHYE Y., SUO C., SCHIRA M., GALETTIS P., MARTIN J.H., YÜCEL M., SOLOWIJ N. : Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users, *Cannabis and Cannabinoid Research*, 2018, 3, (1), 94-107.
Doi : 10.1089/can.2017.0047
19. BELENDIUK K.A., BABSON K.A., VANDREY R., BONN-MILLER M.O. : Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis, *Addictive Behaviors*, 2015, 50, 178-181.
20. BERGAMASCHI M.M., QUEIROZ R.H.C., CHAGAS M.H.N. et al. : Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients, *Neuropsychopharmacology*, 2011, 36, 1219-1226.
Doi : 10.1038/npp.2011.6
21. BERGAMASHI M.M., QUEIROZ R.H., ZUARDI A.W., CRIPPA J.A. : Safety and side effects of cannabidiol, a cannabis sativa constituent, *Current Drug Safety*, 2011, 6, 4, 237-249.
22. BHATTACHARYYA S., MORRISON P.D., FUSAR-POLI P., MARTIN-SANTOS R., ZUARDI A.W., McGUIRE P. et al : Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology, *Neuropsychopharmacology*, 2010, 35, 764-774.
Doi : 10.1038/npp.2009.184
23. BHATTACHARYYA S., WILSON R., APPIAH-KUSI E., O'NEILL A., BRAMMER M., PEREZ J., MURRAY R., ALLEN P., BOSSONG M.G., McGUIRE P. : Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis : A Randomized Clinical Trial, *JAMA Psychiatry*, 2018.
Doi : 10.1001/jamapsychiatry.2018.2309
24. BHATTACHARYYA S. : Cannabidiol As A Treatment In Different Stages Of Psychosis - Efficacy And Mechanisms, *Schizophrenia Bulletin*, 2018, 44, (suppl 1), S27-S27.
25. BIH C.I. et al. : Molecular targets of cannabidiol in neurological disorders, *Neurotherapeutics*, 2015, 12, 4, 699-730.
26. BIS-HUMBERT C., GARCIA-CABRERIZO R., GARCIA-FUSTER M.J. : Decreased sensitivity in adolescent versus adult rats to the antidepressant-like effects of cannabidiol., *Psychopharmacology (Berl)*, 2020.
Doi : 10.1007/s00213-020-05481-4
27. BISOGNO T., HANUS L., De PETROCELLIS L., TCHILIBON S., PONDE D.E., BRANDI I. et al. : Molecular targets for cannabidiol and its synthetic analogues : effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide, *British Journal of Pharmacology*, 2001, 134, 845-852.

28. BLAIR R.E., DESHPANDE L.S., De LORENZO R.J. : Cannabinoids : is there a potential treatment role in epilepsy ?, *Expert Opin Pharmacother*, 2015, 16, 13, 1911-1914.
29. BLASKOVICH M.A.T., KAVANAGH A., RAMU S., LEV, S., CALLAHA, M., THURN M. : Cannabidiol is a Remarkably Active Gram-Positive Antibiotic, in *ASM Microbe Conference*, San Francisco, CA, 2019.
30. BLESSING E.M., STEENKAMP M.M., MANZANARES J., MARMAR C.R. : Cannabidiol as a Potential Treatment for Anxiety Disorders, *Neurotherapeutics*, 2015, 12, 4, 825-836.
Doi : 10.1007/s13311-015-0387-1
31. BOGGS D.L., NGUYEN J.D., MORGENSEN D., TAFFE M.A., RANGANATHAN M. : Clinical and Preclinical Evidence for functional Interactions of Cannabidiol and delta-9-Tetrahydrocannabinol, *Neuropsychopharmacology*, 2018, 43, (1), 142-154.
Doi : 10.1038/npp.2017.209
32. BOGGS D.L., SURTI T., GUPTA A., GUPTA S., NICIU M., PITTMAN B., SCHNAKENBERG MARTIN A.M., THURNAUER H., DAVIES A., D'SOUZA D.C., RANGANATHAN M. : The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial, *Psychopharmacology*, 2018.
Doi : 10.1007/s00213-018-4885-9.
33. BONN-MILLER M.O., LOFLIN M.J.E., THOMAS B.F. et al. : Labeling accuracy of cannabidiol extracts sold online, *JAMA*, 2017, 318, 1708.
34. BOOZ G.W. : Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress, *Free Radical Biology and Medicine*, 2011, 51, 5, 1054-1061.
Doi : 10.1016/j.freeradbiomed.2011.01.007
35. BORGAN F. et al. : In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis, *JAMA Psychiatry*, 2019.
Doi : 10.1001/jamapsychiatry.2019.1427
36. BORGWARDT S.J. et al. : Neural basis of delta-9-tetrahydrocannabinol and cannabidiol : effects during response inhibition, *Biological Psychiatry*, 2008, 64, 966-973.
Doi : 10.1016/j.biopsych.2008.05.011
37. BRAND E.J., ZHAO Z. (2017) : Cannabis in Chinese Medicine : Are Some Traditionnel Indications Referenced in Ancient Literature Related to cannabinoids, *Frontiers in Pharmacology*, 2017, 8, 108.
38. BRITCH S.C., WILEY J.L., ZHIHAO Y., CLOWERS B.H., CRAFT R.M. : Cannabidiol-Delta9-tetrahydrocannabinol interactions on acute pain and locomotor activity, *Drug and Alcohol Dependence*, 2017, 175, 187-197.
39. BROWN J.D., WINTERSTEIN A.G. : Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use, *Journal of Clinical Medicine*, 2019, 8, 989.
Doi : 10.3390/jcm8070989
40. BRUNT T.M., van GENUGTEN M., HÖNER-SNOEKEN K., van de VELDE M.J., NIESINK R.J. : Therapeutic satisfaction and subjective effects of different strains of pharmaceutical-grade cannabis, *Journal of Clinical Psychopharmacology*, 2014, 34, (3), 344-349.
Doi : 10.1097/JCP.0000000000000129
41. BURSTEIN S. : Cannabidiol (CBD) and its analogs : a review of their effects on inflammation, *Bioorganic & Medicinal Chemistry*, 2015, 23, 1377-1385.

42. CALAPAI G., MANNUCCI C., CHINOU I., CARDIA L., CALAPAI F., SORBARA E.E., FIRENZUOLI B., RICCA V., GENNINI G.-F., FIRENZUOLI F. : Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry, *Hindawi - Evidence-Based Complementary and Alternative Medicine*, 2019, Article ID 2509129, 11 pages.
Doi : 10.1155/2019/2509129
43. CALLEJAS G.H., FIGUEIRA R.L., GONÇALVES F.L.L., VOLPE F.A.P., ZUARDI A.W., CRIPPA J.A./, HALLAK J.E., SBRAGIA L. : Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastroschisis rat model, *Brazilian Journal of Medical and Biological Research*, 2018, 51, (5), e7132
Doi : 10.1590/1414-431X20177132
44. CALPE-LÓPEZ C., GARCIA-PARDO M.P., AGUILAR M.A. : Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders : A Review of Possible Mechanisms, *Molecules*, 2019, 24, 2583.
Doi : 10.3390/molecules24142583
45. CAMPOS A.C., MOREIRA F.A., GOMES F.V. et al. : Multiples mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders, *Philosophical Transactions of the Royal Society B*, 2012, 367, 1607, 3364-3378.
Doi : 10.1098/rstb.2011.0389
46. CAMPOS A.C., FERREIRA F.R., GUIMARAES F.S. : Cannabidiol blocks long-lasting behavioral consequences of predator threat stress : possible involvement of 5HT1A receptors, *Journal of Psychiatric Research*, 2012, 46, (11), 1501-1510.
47. CAMPOS A.C., ORTEGA Z., PALAZUELOS J. et al. : The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis : Involvement of the endocannabinoid system, *International Journal of Neuropsychopharmacology*, 2013, 16, 1407-1419.
48. CAMPOS A.C., BRANT F., MIRANDA A.S., MACHADO F.S., TEIXERA A.L. : Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria, *Neuroscience*, 2015, 289, 166-180.
49. CAMPOS A.C., FOGACA M.V., SCARANTE F.F. et al. : Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders, *Frontiers in Pharmacology*, 2017, 8, article 269.
Doi : 10.3389/fphar.2017.00269
50. CAPANO A., WEAVER R., BURKMAN E. : Evaluation of the effects of CBD hemps extract on opioid use and quality of life indicators in chronic pain patients : a prospective cohort study, *Postgraduate Medicine*, 2020, 132, 1, 56-61.
Doi : 10.1080/00325481.2019.1685298
51. CARLINI E.A., CUNHA J.M. : Hypnotic and antiepileptic effects of cannabidiol, *The Journal of Clinical Pharmacology*, 1981, 21, 417-427.
52. CASTILLO A., TOLON M.R., FERNANDEZ-RUIZ J., ROMERO J., MARTINEZ-ORGADO J. : The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors, *Neurobiology of Disease*, 2010, 37, (2), 434-40.
53. CEPRIAN M., JIMENEZ-SANCHEZ L., VARGAS C., BARATA L., HIND W., MARTINEZ-ORGADO J. : Cannabidiol reduces brain damage and improves functional recovery in a neonatal rat model of arterial ischemic stroke, *Neuropharmacology*, 2017, 116, 151-159.
54. CEPRIAN M., VARGAS C., GARCIA-TOSCANO L., PENNA F., JIMENEZ-SANCHEZ L., ACHICALLENDE S., ELEZGARAI I., GRANDES P., HIND W., PAZOS M.R., MARTINEZ-ORGADO J. : Cannabidiol Administration Prevents Hypoxia-Ischemia-Induced

Hypomyelination in Newborn Rats, *Frontiers in Pharmacology*, 2019, Vol 10, Article 1131.

Doi : 10.3389/fphar.2019.01131

55. CHAGAS M.H., CRIPPA J.A., ZUARDI A.W., HALLAK J.E., MACHADO-de-SOUSA J.P., HIROTSU C., MAIA L., TUFIK S., ANDERSEN M.L. : Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats, *Journal of Psychopharmacology*, 2013, 27, (3), 312-316.
56. CHAGAS M.H., ZUARDI A.W., TUMAS V., PENA-PEREIRA M.A., SOBREIRA E.T., BERGAMASHI M.M., Dos SANTOS A.C., TEIXERA A.L., HALLAK J.E., CRIPPA J.A. : Effects of cannabidiol in the treatment of patients with Parkinson's disease : an exploratory double-blind trial, *Journal of Psychopharmacology*, 2014, 28, (11), 1088-1098.
57. CHEN J., HOU C., CHEN X., WANG D., YANG P., HE X., ZHOU J., LI H. : Protective effect of cannabidiol on hydrogen peroxideinduced apoptosis, inflammation and oxidative stress in nucleus pulposus cells, *Molecular Medicine Reports*, 2016, 14, (3), 2321-2327.
58. CHEN K.A., FARRAR M., CARDAMONE M., GILL D. et al. : Cannabidiol for treating drug-resistant epilepsy in children : the New South Wales experience, *Medical Journal of Australia*, 2018 August 13.
59. CHIU P., OLSEN D.M., BORYS H.K. et al : The influence of cannabidiol and delta 9-tetrahydrocannabinol on cobalt epilepsy in rats, *Epilepsia*, 1979, 20, 365-375.
60. CHYE Y., CHRISTENSEN E., SOLOWIJ N., YÜCEL M. : The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder, *Frontiers in Psychiatry*, 2019, Vol 10, Article 63.
Doi : 10.3389/fpsyg.2019.00063
61. CILIO M.R., THIELE E.A., DEVINSKY O. : The case for assessing cannabidiol in epilepsy, *Epilepsia*, 2014, 55, 6, 787-790.
62. CLEIREC G., POLOMENI P. : Le Cannabidiol, l'autre cannabinoïde présent dans le cannabis : une piste thérapeutique prometteuse ?, *Revue SWAPS*, 2019, n°90, "Du Cannabis Thérapeutique à la Régulation".
<http://vih.org/20190520/cannabidiol-lautre-canabinoide-present-cannabis-piste-therapeutique-prometteuse/141891>
63. COLLIZI M., BHATTACHARYYA S. : Does Cannabis Composition Matter ? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition, *Current Addiction Reports*, 2017, 4, (2), 62-74
Doi : 10.1007/s40429-017-0142-2
64. CONSROE P.F., WOLKIN A. : Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats, *Journal of Pharmacology and Experimental Therapeutics*, 1977, 201, 1, 26-32.
65. CONSROE P.F., WOLKIN A.L. : Anticonvulsant interaction of cannabidiol and ethosuximide in rats, *Journal of Pharmacy and Pharmacology*, 1977, 29, 500-501.
66. CONSROE P.F., MARTIN A., SINGH V. : Antiepileptic potential of cannabidiol analogs, *The Journal of Clinical Pharmacology*, 1981, 21, 8-9, 428-436.
67. CONSROE P., SANDYK R., SNIDER S.R. : Open label evaluation of cannabidiol in dystonic movement disorders, *International Journal of Neuroscience*, 1986, 30, (4), 277-282.
68. CONSROE P. et al. : Controlled clinical trial of cannabidiol in Huntington's disease, *Pharmacology Biochemistry and Behavior*, 1991, 40, 3, 701-708.
Doi : 10.1016/0091-3057(91)90386-G

69. CONSROE P., KENNEDY K., SCHRAM K. : Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans, *Pharmacology Biochemistry and Behavior*, 1991, 40, 517-522.
70. CONSROE P., SANDYK R. : Potential role of cannabinoids for therapy of neurological disorders, in Murphy L., Bartke A. eds, *Marijuana/Cannabinoids, Neurobiology and Neurophysiology*, Boca Raton, CRC Press, 1992, 459, 524.
71. COUCH D.G., TASKER C., THEOPHILIDOU E. et al. : Cannabidiol and palmitoyl-ethanolamide are anti-inflammatory in the acutely inflamed human colon, *Clinical Science (London)*, 2017, 131, 2611-2626.
72. CRIPPA J.A., ZUARDI A.W., GARRIDO G.E., WICHERT-ANA L., GUARNIERI R., FERRARI L., AZEVEDO-MARQUES P.M., HALLAK J.E., McGUIRE P.K., FILHO BUSSATO G. : Effects of cannabidiol (CBD) on regional cerebral blood flow, *Neuropharmacology*, 2004, 29, (2), 417-426.
PMID : 14583744
73. CRIPPA J.A., DERENUSSON G.N., FERRARI T.B., WICHERT-ANA L., DURAN F.L., MARTIN-SANTOS R., SIMOES M.V., BHATTACHARYYA S., FUSAR-POLI P., ATAKAN Z., SANTOS FILHO A., FREITAS-FERRARI M.C., McGUIRE P.K., ZUARDI A.W., BUSATTO G.F., HALLAK J.E. : Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report, *Journal of Psychopharmacology*, 2011, 25, (1), 121-130.
74. CRIPPA J.A., HALLAK J.E., MACHADO-de-SOUZA J.P., QUEIROZ R.H., BERGAMASHI M., CHAGAS M.H., ZUARDIA.W. : Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report, *Journal of Clinical Pharmacy and Therapeutics*, 2013, 38, (2), 162-164.
75. CRIPPA J.A., HALLAK J.E., ABILIO V.C., de LACERDA A.L., ZUARDI A.W. : Cannabidiol and Sodium Nitroprusside : Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis, *CNS and Neurological Disorders - Drug Targets*, 2015, 14, 8, 970-978.
Doi : 10.2174/18715273146661500909113930
76. CRIPPA J.A., GUIMARAES F.S., CAMPOS A.C., ZUARDI A.W. : Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD) : Toward a New Age, *Frontiers in Immunology*, 2018, 9, article 2009, 16 p.
Doi : 10.3389/fimmu.2018.02009
77. CUNHA J.M., CARLINI E.A., MECHOULAM R. et al. : Chronic administration of cannabidiol to healthy volunteers and epileptic patients, *Pharmacology*, 1980, 21, (3), 175-185.
78. DALTON W.S., MARTZ R., RODDA B.E., LEMBERGER L., FORNEY R.B. : Influence of cannabidiol on secobarbital effects and plasma kinetics, *Clinical Pharmacology & Therapeutics*, 1976, 20, (6), 695-700.
79. DALTON W.S., MARTZ R., LEMBERGER L., RODDA B.E., FORNEY R.B. : Influence of cannabidiol on delta-9-tetrahydrocannabinol effects, *Clinical Pharmacology and Therapeutics*, 1976, 19, 300-309.
80. DAS R.K., KAMBOJ S.K., RAMADAS M., YOGAN K., GUPTA V., REDMAN E., CURRAN H.V., MORGAN C.J. : Cannabidiol enhances consolidation of explicit fear extinction in humans, *Psychopharmacology (Berl)*, 2013, 226, (4), 781-792.
81. Da SILVA V.K., de FREITAS B.S., DORNELLES V.C. et al. : Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration : Reversal by Cannabidiol, *Brain Research Bulletin*, 2018, 139, 1-8.

Doi : 10.1016/j.brainresbull.2018.01.014

82. DAVIES C., BHATTACHARYYA S. : Cannabidiol as a potential treatment for psychosis, *Therapeutic Advances in Psychopharmacology*, 2019, Vol. 9, 1-16.
Doi : 10.1177/2045125319881916
83. De CARVALHO C.R., TAKAHASHI R.N. : Cannabidiol disrupts the reconsolidation of contextual drug-associated memories in wistar rats, *Addiction Biology*, 2017, 22, (3), 742-751.
84. De FILIPPIS D., ESPOSITO G., CIRILLO C., CIPRIANO M., De WINTER B.Y., SCUDERI C., SARANELLI G., CUOMO R., STEARDO L., De MAN J.G., IUVONE T. : Cannabidiol reduces intestinal inflammation through the control of neuro-immune axis, *PLoS One*, 2011, 6, (12), e28159.
85. DEIANA S., WATANABE A., YAMASAKI Y. et al. : Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ^9 -tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour, *Psychopharmacology (Berl)*, 2012, 219, 859-873.
86. DEIANA S. : Medical use of cannabis. Cannabidiol : a new light for schizophrenia ?, *Drug Testing and Analysis*, 2013, 5, (1), 46-51.
87. De MELLO SCHIER A., de OLIVEIRA RIBEIRO N.P., COUTINHO D.S., MACHADO S., ARIAS-CARRION O., CRIPPA J.A., ZUARDI A.W., NARDI A.E., SILVA A.C. : Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol : A Chemical Compounds of Cannabis Sativa, *CNS & Neurological Disorders – Drug Targets*, 2014, 13, 953-960.
88. De PETROCELLIS L., LIGRESTI A., SCHIANO MORIELLO A., LAPPELLI M., VERDE R., STOTT C.G., CRISTINO L., ORLANDO P., Di MARZO V. : Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo : pro-apoptotic effects and underlying mechanisms, *British Journal of Pharmacology*, 2013, 168, (1), 79-102.
89. De TERNAY J., NAASSILA M., NOURREDINE M., LOUVET A., BAILLY F., SESCOUSSE G., MAURAGE P., COTTENCIN O., CARRIERI P.M., ROLLAND B. : Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain, *Frontiers in Pharmacology*, 2019, Volume 10, Article 627.
Doi : 10.3389/fphar.2019.00627
90. DENG L., NG L., OZAWA T., STELLA N. : Quantitative Analyses of Synergetic Response between Cannabidiol and DNA-Damaging Agents on the proliferation and Viability of Gliosblastoma and Neural Progenitor Cells in Culture, *Journal of Pharmacology and Experimental Therapeutics*, 2017, 360, (1), 215-224.
91. DETYNIECKI K., HIRSCH L.J. : Cannabidiol for epilepsy : trying to see through the haze, *The Lancet*, 2016, 15, 3, 235-237.
92. DEVINSKY O., CILIO M.R., Di MARZO V., FRIEDMAN D. et al. : Cannabidiol : pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders, *Epilepsia*, 2014, 55, 6, 791-802.
Doi : 10.1111/epi.12631
93. DEVINSKY O., MARSH E., FILLOUX F., BLUVSTEIN J., CILIO M.R. et al. : Cannabidiol in patients with treatment-resistant epilepsy : an open-label interventional trial, *Lancet Neurology*, 2015.
94. DEVINSKY O., CROSS J.H., WRIGHT S. : Trial of Cannabidiol for Drug -Resistant Seizures in the Dravet Syndrome, *New England Journal of Medicine*, 2017, 376, 21, 2011-2020.

95. DEVINSKY O., PATEL A.D., CROSS J.H. et al. : Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome, *New England Journal of Medicine*, 2018, 378, 1888-1897.
96. DEVINSKY O., PATEL A.D., THIELE E.A. et al. : Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome, *Neurology*, 2018, 90, e1204-e1211.
97. DEVINSKY O., VERDUCCI C., THIELE E.A., et al. : Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes, *Epilepsy & Behavior*, 2018, 86, 131-137.
98. DHITAL S., STOKES J.V., PARK N., SEO K.S., KAPLAN B.L. : Cannabidiol (CBD) induces functional Tregs in response to low-level T cell activation, *Cellular Immunology*, 2017, 312, 25-34.
99. DIRIKOC S., PRIOLA S.A., MARELLA M., ZSÜRGER N., CHABRY J. : Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity, *Journal of Neuroscience*, 2007, 27, (36), 9537-9544.
100. DJEZZAR S. : Evaluation du potentiel d'abus et de dépendance et du potentiel thérapeutique du cannabidiol (Avis), ANSM, séance n°11, *Commission des Stupéfiants et des Psychotropes, Compte rendu de la séance du 25 juin 2015*, p17/25.
101. Dos SANTOS R.G., HALLAK J.E., LEITE J.P., ZUARDI A.W., CRIPPA J.A. : Phytocannabinoids and epilepsy, *Journal of Clinical Pharmacy and Therapeutics*, 2015, 40, 2, 135-143.
102. Dos SANTOS R.G., HALLAK J.E.C., ZUARDI W., de SOUZA J.A. : Cannabidiol for the Treatment of Drug Use Disorders, Chapter 97, in "Handbook of Cannabis and Related Pathologies. Biology, Pharmacology, Diagnosis, and Treatment", 2017, pp. 939-946.
Doi : 10.1016/B978-0-12-800756-3.00113-7
103. DUDASOVA A., KEIR S.D., PARSONS M.E., MOLLEMAN A., PAGE C.P. : The effects of cannabidiol on the antigen-induced contraction of airways smooth muscle in the guinea-pig, *Pulmonary Pharmacology and Therapeutics*, 2013, 26, (3) 373-379.
104. ELBATSH M.M., ASSAREH N., MARSDEN C.A., KENDALL D.A. : Anxiogenic-like effects of chronic cannabidiol administration in rats, *Psychopharmacology (Berl)*, 2012, 221, (2), 239-247.
105. ELBAZ M., AHIRWAR D., RAVI J., NASSER M.W., GANJU R.K. : Novel role of cannabinoid receptor 2 in inhibiting EGF/EGFR and IGF-I/IGF-IR pathways in breast cancer, *Oncotarget*, 2017, 8, (18), 29668-29678.
106. ELLIOTT D.M., SINGH N., NAGARKATTI M., NAGARKATTI P.S. : Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells; *Frontiers in Immunology*, 2018, Vol 9, Article 1782, 1-12.
Doi : 10.3389/fimmu.2018.01782
107. ELMES M.W., KACZOCHA M., BERGER W.T. et al. : Fatty acidbinding proteins (FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), *Journal of Biological Chemistry*, 2015, 290, 8711-8721.
108. ELSAID S., KLOIBER S., Le FOLL B. : Effects of cannabidiol (CBD) in neuropsychiatric disorders : A review of preclinical and clinical findings, *Progress in Molecular Biology and Translational Science*, 2019, 167, 25-75.
Doi : 10.1016/bs.pmbts.2019.06.005
109. ENGLUND A., MORRISON P.D., NOTTAGE J., HAQUE D., KANE F., BONACCORSO S., STONE J.M., REICHENBERG A., BRENNER R., HOLT D.,

- FEILDING A., WALKER L., MURRAY R.M., KAPUR S. : Cannabidiol inhibits THC-elicted paranoid symptoms and hippocampal-dependent memory impairment, *Journal of Psychopharmacology*, 2013, 27, (1), 19-27.
Doi : 10.1177/0269881112460109
110. ESPOSITO G. et al. : The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells, *Journal of Molecular Medicine (Berl)*, 2006, 84, 3, 253-258.
111. ESPOSITO G., SCUDERI C., VALENZA M., TOGNA G.I., LATINA V., De FILIPPIS D., CIPRIANO M., CARRATU M.R., IUVONE T., STEARDO L. : Cannabidiol Reduces A β -Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPAR γ Involvement, *PLoS One*, 2011, 6, (12), e28668.
Doi : 10.1371/journal.pone.0028668
112. FAKHOURY M. : Could cannabidiol be used as an alternative to antipsychotics ?, *Journal of Psychiatric Research*, 2016, 80, 14-21.
Doi : 10.1016/j.jpsychires.2016.05.013
113. FAKHOURY M. : Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia, *Molecular Neurobiology*, 2017, 54, (1), 768-778.
Doi : 10.1007/s12035-016-9697-5
114. FARRIMOND J.A., WHALLEY B.J., WILLIAMS C.M. : Cannabinol and cannabidiol exert opposing effects on rat feeding patterns, *Psychopharmacology (Berl)*, 2012, 223, (1), 117-129.
115. FASINU P.S., PHILLIPS S., ELSOHLY M.A., WALKER L.A. : Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents, *Pharmacotherapy*, 2016, 36, (7), 781-796.
Doi : 10.1002/phar.1780
116. FEINSHTEIN V., EREZ O., BEN-ZVI Z., EREZ N., et al. : Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines, *PeerJ*, 2013, 1, e153.
117. FENG Y., CHEN F., YIN T., XIA Q., LIU Y., HUANG G., ZHANG J., OYEN R., NI Y. : Pharmacologic Effects of Cannabidiol on Acute Reperfused Myocardial Infarction in Rabbits : Evaluated With 3.0T Cardiac Magnetic Resonance Imaging and Histopathology, *Journal of Cardiovascular Pharmacology*, 2015, 66, (4), 354-363.
118. FERNANDEZ-RUIZ J., GONZALES S., ROMERO J., RAMOS J.A. : Cannabinoids in neurodegeneration and neuroprotection, in « *Cannabinoids as Therapeutics* », Ed. R. Mechoulam, Birkhäuser Verlag, Switzerland, 2005, 79-109.
119. FERNANDEZ-RUIZ J., SAGREDO O., PAZOS M.R., GARCIA C., PERTWEE R., MECHOULAM R., MARTINEZ-ORGADO J. : Cannabidiol for neurodegenerative disorders : important new clinical applications for this phytocannabinoid ?, *The British Journal of Clinical Pharmacology*, 2013, 75, (2), 323-333.
120. FISHER T., GOLAN H., SCHIBY G., PRIHEN S., SMOUM R., MOSHE I., PESHES-YALOZ N., CASTIEL A., WALDMAN D., GALILY R., MECHOULAM R., TOREN A. : In vitro and in vivo efficacy of non-psychotropic cannabidiol in neuroblastoma, *Current Oncology*, 2016, 23, (2), S15-22.
121. FOGACA M.V. et al. : Cannabinoids, Neurogenesis and Antidepressant Drugs : is there a Link ?, *Current Neuropharmacology*, 2013, 11, (3), 263-275.
122. FOGAÇA M.V., CAMPOS A.C., COELHO L.D., DUMANR.S., GUIMARAES F.S. : The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system : Role of neurogenesis and dendritic remodeling, *Neuropharmacology*, 2018, 135, 22-23.

Doi : 10.1016/j.neuropharm.2018.03.001

123. FORESTOR B.P. : Open-label trial of a cannabidiol solution for the treatment of behavioral symptoms in older adults with Alzheimer's Dementia, 2019.
https://clinicaltrial.gov/ct2/show/NCT04075435?term=CBD&cond=Anxiety&dr_aw=2rank=5
124. FOUAD A.A., AL-MULHIN A.S., JRESAT I. : Cannabidiol treatment ameliorates ischemia/reperfusion renal injury in rats, *Life Science*, 2012, 91, (7-8), 284-292.
125. FRIEDMAN D., CILIO M.R., TILTON N. et al. : The effects of Epidiolex (Cannabidiol) on serum levels of concomitant anti-epileptic drugs in children and young adults with treatment resistant epilepsy in an expand access program, *Annual Meeting of the American Epilepsy Society, Seattle, December 5-9, 2014*, Abstract.
126. FRIEDMAN D., DEVINSKY O. : Cannabinoids in the Treatment of Epilepsy, *New England Journal of Medicine*, 2015, 373, 1048-1058.
127. FRIEDMAN D., FRENCH J.A., MACCARRONE M. : Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders, *Lancet Neurology*, 2019.
Doi : 10.1016/S1474-4422(19)30032-8
128. FUSAR-POLI P., CRIPPA J., BHATTACHARYYA S. et al. : Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing, *Archives of General Psychiatry*, 2009, 66, (1), 95-105.
Doi : 10.1001/archgenpsychiatry.2008.519
129. FUSAR-POLI P., ALLEN P., BHATTACHARYYA S., CRIPPA J.A., MECHELLI A., BORGWARDT S., MARTIN-SANTOS R., SEAL M.L., O'CARROL C., ATAKAN Z., ZUARDI A.W., McGUIRE P. : Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol, *International Journal of Neuropsychopharmacology*, 2010, 13, (4), 421-432.
PMID : 19775500
130. GAGNON-HEBERT F.-O. : Le CBD est-il psychoactif ?, *La Lettre du RESPADD*, Octobre 2019, 36, 4-5.
<https://www.respadd.org/lettre-n36-octobre-2019/>
131. GALLILY R., YEKHTIN Z., HANUS L.O. : Overcoming the Bell-Shaped Dose-Response of cannabidiol by Using Cannabis Extract Enriched in Cannabidiol, *Pharmacology & Pharmacy*, 2015, 6, 75-85.
Doi : 10.4236/pp.2015.62010
132. GARCIA C., PERTWEE R., MECHOULAM R., MARTINEZ-ORGADO J. : Cannabidiol for neurodegenerative disorders : important new clinical applications for this phytocannabinoid ?, *British Journal of Clinical Pharmacology*, 2013, 75, (2), 323-33.
133. GARCIA-GUTIERREZ M.S., NAVARRETE F., VIUDEZ-MARTINEZ A., GASPARYAN A., CAPARROS E., MANZANARES J. : Cannabidiol and Cannabis Use Disorder, Chapter in book "Cannabis Use Disorders", 2018, pp 31-42.
Doi : 10.1007/978-3-319-90365-1_5
134. GASTON T.E., BEBIN E.M., CUTTER G.R., et al. : Interactions between cannabidiol and commonly used antiepileptic drugs, *Epilepsia*, 2017, 58, (9), 1586-1592.
135. GASTON T.E., BEBIN E.M., CUTTER G.R., et al. : Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label expanded access program, *Epilepsy & Behavior*, 2019, 98, 201-206.

136. GEFFREY A.L., POLLACK S.F., BRUNO P.L. et al. : Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy, *Epilepsia*. 2015, 56, 1246-1251.
137. GENARO K., FABRIS D., ARANTES A.L.F., ZUARDI A.W., CRIPPA J.A.S., PRADO W.A. : Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision pain in Rats, *Frontiers in Pharmacology*, 2017, 8, Article 391, 1-12.
Doi : 10.3389/fphar.2017.00391
138. GIACOPPO S., GALUPPO M., POLLASTRO F., GRASSI G., BRAMANTI P., MAZZON E. : A new formulation of cannabidiol in creams shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis, *Daru*, 2015, 23, 48.
139. GIACOPPO S., SOUNDARA RAJAN T., GALUPPO M., POLLASTRO F., GRASSI G., BRAMANTI P., MAZZON E. : Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis, *European Review for Medical and Pharmacological Sciences*, 2015, 19, 4906-4919.
140. GIACOPPO S., POLLASTRO F., GRASSI G., BRAMANTI P., MAZZON E. : Target regulation of PI3K/Akt/mTOR pathway by cannabidiol in treatment of experimental multiple sclerosis, *Fitoterapia*, 2016, 116, 77-84.
141. GLOSS D., VICKREY B. : Cannabinoids for epilepsy, *Cochrane Database Systematic Review*, 2012, 6.
142. GOBBI G. : A role for cannabidiol in Psychiatry ? Keep calm and follow the drug development rules, *The World Journal of Biological Psychiatry*, 2019, 20, (2), 98-100.
Doi : 10.1080/15622975.2019.1584680
143. GOBIRA P.H., VILELA L.R., GONCALVES B.D., SANTOS R.P., de OLIVEIRA A.C., VIEIRA L.B., AGUIAR D.C., CRIPPA J.A., MOREIRA F.A. : Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice. Possible role of the mTOR pathway and reduction in glutamate release, *Neurotoxicology*, 2015, 50, 116-21.
Doi : 10.1016/j.neuro.2015.08.007
144. GOFSHTEYN J.S., WILFONG A., DEVINSKY O., BLUVSTEIN J., MARSH E.D. et al. : Cannabidiol as a Potential Treatment for Febrile Infection-Related Epilepsy Syndrome (FIRES) in the Acute and Chronic Phases, *Journal of Child Neurology*, 2016.
145. GOMES F.V., Del BEL E.A., GUIMARAES F.S. : Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice, *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 2013, 46, 43-47.
146. GOMES F.V., LLORENTE R., Del BEL E.A., VIVEROS M.P., LOPEZ-GALLARDO M., GUIMARAES F.S. : Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol, *Schizophrenia Research*, 2015, 164, (1-3), 155-163.
Doi : 10.1016/j.schres.2015.01.015
147. GONZALEZ-CUEVAS G., MARTIN-FARDON R., KERR T.M., STOUFFER D.G., PARSONS L.H., HAMMELL D.C., BANKS S.L., STINCHCOMB A.L., WEISS F. : Unique treatment potential of cannabidiol for the prevention of relapse to drug use :

Preclinical proof of principal, *Neuropsychopharmacology*, 2018, 43, (10), 2036-2045.

Doi : 10.1038/S41386-018-0050-8

148. GONZALEZ-GARCIA C., MORENO TORRES I., GARCIA-HERNANDEZ R., CAMPOS-RUIZ L., ESPARRAGOZA L.R., CORONADO M.J., GRANDE A.G., GARCIA-MERINO A., SANCHEZ LOPEZ A.J. : Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis, *Experimental Neurology*, 2017, 298, Part A, 57-67.
Doi : 10.1016/j.expneurol.2017.08.017
149. GRAY R.A., STOTT C.G., JONES N.A., Di MARZO V., WHALLEY B.J. : Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent, *Cannabis and Cannabinoid Research*, 2019, 1-5.
Doi : 10.1089/can.2019.0028
150. GREKOPOULOS J.E. : Construction and Validation of Quantification Methods for Determining the Cannabidiol Content in Liquid Pharma-Grade Formulations by Means of Near-Infrared Spectroscopy and Partial Least Squares Regression, *Medical Cannabis and Cannabinoids*, 2019, 2, 43-55.
Doi : 10.1159/000500266
151. GRINSPOON P. : Cannabidiol (CBD) – what we know and what we don't, Harvard Medical School, *Harvard Health Blog*, 2018, August 24.
<https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476>
152. GROTHENHERMEN F. : Pharmacokinetics and pharmacodynamics of cannabinoids, *Clinical Pharmacokinetics*, 2003, 42, (4), 327-360.
PMID : 12648025
153. GROTHENHERMEN F. : Cannabinoids, *Current Drug Targets - CNS and Neurological Disorders*, 2005, 4, 507-530.
154. GROTHENHERMEN F. : Les cannabinoides et le système des endocannabinoides, *Cannabinoids*, 2006, 1, 1, 10-15.
155. GROTHENHERMEN F., RUSSO E., ZUARDI A.W. : Even High Doses of Oral Cannabidiol Do Not Cause THC-Like Effects in Humans : Comment on Merrick et al., *Cannabis and Cannabinoid Research*, 2016, 1, (1), 102-112, (Doi : 10.1089/can.2015.0004), *Cannabis and Cannabinoid Research*, 2017, 2, (1), 1-4.
Doi : 10.1089/can.2016.0036.
156. GROTHENHERMEN F. : Chanvre en Médecine. Redécouverte d'une plante médicinale. Guide pratique des applications thérapeutiques du Cannabis, du THC et du CBD, Edition Solanacée, 2017.
157. GROTHENHERMEN F. : CBD. Un cannabinoïde au vaste potentiel thérapeutique, Editions Solanacée, Suisse, 2018, 93 p.
158. GUIMARAES F.S., CHIARETTI T.M., GRAEFF F.G., ZUARDI A.W. : Antianxiety effect of cannabidiol in the elevated plus-maze, *Psychopharmacology*, 1990, 100, 558-559.
159. GUINGUIS R., RUIZ M.I., RADA G. : Is cannabidiol an effective treatment for schizophrenia ?, *Medwave*, 2017, 17, 7, e7010
Doi : 10.5867/medwave.2017.07.7010

160. GURURAJAN A., TAYLOR D.A., MALONE D.T. : Effects of cannabidiol in a MK-801-rodent model of aspects of schizophrenia, *Behavioral Brain Research*, 2011, 222, (2), 299-308.
Doi : 10.1016/j.bbr.2011.03.053
161. GURURAJAN A., TAYLOR D.A., MALONE D.T. : Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats, *Journal of Psychopharmacology*, 2012.
Doi : 10.1177/0269881112441865
162. GURURAJAN A., MALONE D.T. : Does Cannabidiol have a role in the treatment of schizophrenia ? *Schizophrenia Research*, 2016, 176, (2-3), 281-290.
163. HAHN B. : The Potential of Cannabidiol Treatment for Cannabis Users with Recent-Onset Psychosis, *Schizophrenia Bulletin*, 2018, 44, 1, 46-53.
[www.medscape.com/viewarticle/893134 print](http://www.medscape.com/viewarticle/893134)
164. HAMELINK C., HAMPSON A., WINK D.A., EIDEN L.E., ESKAY R.L. : Comparison of cannabidiol, antioxidants, and diuretic in reversing binge ethanol-induced neurotoxicity, *Journal of Pharmacology & Experimental Therapeutics*, 2005, 314, (2), 780-788.
165. HAMMEL D.C., ZHANG L.P., MA F., ABSHIRE S.M., McLLWRATH S.L., STINCHCOMB A.L., WESTLUND K.N. : Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis, *European Journal of Pain*, 2016, 20, (6), 936-948.
166. HAMPSON A.J., GRIMALDI M., AXELROD J., WINK D. : Cannabidiol and (-) Delta-9-tetrahydrocannabinol are neuroprotective antioxidants, *PNAS Proceedings of the National Academy of Sciences of USA*, 1998, 95, 8268-8273.
167. HAMPSON A.J., GRIMALDI M., LOLIC M., WINK D., ROSENTHAL R., AXELROD J. : Neuroprotective Antioxidants from Marijuana, *Annals of the New York Academy of Science*, 2006, 899, 1.
168. HANEY M., MALCOLM R.J., BABALONIS S. et al. : Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis, *Neuropsychopharmacology*, 2016, 41, 1974-1982.
169. HAO E., MUKHOPADHYAY P., CAO Z., ERDELYI K., HOLOVAC E., LIAUDET L., LEE W.S., HASKO G., MECHOULAM R., PACHER P. : Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis, *Molecular Medicine*, 2015, 6, (21), 38-45.
170. HARRIS H.M., SUFKA K.J., GUL W., ELSOHLY M.A. : Effects of Delta-9-Tetrahydro-cannabinol and Cannabidiol on Cisplatin-Induced Neuropathy in Mice, *Planta Medica*, 2016, 82, (13), 1169-1172.
171. HAUSMAN-KEDEM M., MENASCU S., KRAMER U. : Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study, *Brains & Development*, 2018, 40, (7), 544-551.
Doi : 10.1016/j.braindev.2018.03.013
172. HAY G.L., BARACZ S.J., EVERETT N.A., ROBERTS J., COSTA P.A., ARNOLD J.C., McGREGOR I.S., CORNISH J.L. : Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats, *Journal of Psychopharmacology*, 2018, 32, (12), 1369-1378.
Doi : 10.1177/0269881118799954
173. HAZEKAMP A., FISCHEDICK J.T. : Cannabis – From Cultivar to chemovar, *Drug Testing & Analysis*, 2012, 4, (7-8), 660-667.

174. HAZEKAMP A. : The trouble with CBD oil, *Medical Cannabis Cannabinoids*, 2018, 1, 65-72.
175. HEDGE V.L., NAGARKATTI P.S., NAGARKATTI M. : Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol, *PLoS One*, 2011, 6, (4), e18281.
176. HEDGE V.L., SINGH U.P., NAGARKATTI P.S., NAGARKATTI M. : Critical Role of Mast Cells and Peroxisome Proliferator-Activated Receptor gamma in the induction of Myeloid-Derived Suppressor Cells by Marijuana Cannabidiol In Vivo, *The Journal of Immunology*, 2015, 194, 5211-5222.
Doi : 10.4049/jimmunol.1401844
177. HERNANDEZ-CERVANTES R., MENDEZ-DIAZ M., PROSPERO-GARCIA O., MORALES-MONTOR J. : Immunoregulatory Role of Cannabinoids during Infectious Disease, *Neuroimmunomodulation*, 2017, 24, 183-199.
Doi : 10.1159/000481824
178. HESS E.J., MOODY KA, GEFFREY A.L. et al. : Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex, *Epilepsia*, 2016, 57, 1617-1624.
179. HILL A.J., HILL T.D.M., WHALLEY B.J. : The Development of Cannabinoid Based Therapies for Epilepsy, *Molecular, Pharmacological, Behavioral and Clinical Feature*, 2013, 164-24.
180. HIND W.H., ENGLAND T.J., O'SULLIVAN S.E. : Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPAR and 5-HT1A receptors, *British Journal of Pharmacology*, 201, 173, (5), 815-825.
Doi : 10.1111/bph.13368
181. HINDOCHA C., FREEMAN T.P., SCHAFER G., GARDENER C., DAS R.K., MORGAN C.J.A., CURRAN H.V. : Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition : A randomised, double-blind, placebo-controlled study in cannabis users, *European Neuropsychopharmacology*, 2015, 25, 325-334.
Doi : 10.1016/j.euroneuro.2014.11.014
182. HINDOCHA C., FREEMAN T.P., GRABSKI M., CRUDGINGTON H., DAVIES A.C., STROUD J.B., DAS R.K., LAWN W., MORGAN C.J.A., CURRAN H.V. : The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers, *Scientific Reports*, 2018, 8, 7568, 1-7.
Doi : 10.1038/s41598-018-25846-2
183. HLOŽEK T., UTTL L., KADE ÁBEK L., BALÍKOVÁ M., LHOTKOV E., HORSLEY R.R. et al. : Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC, *European Neuropsychopharmacology*, 2017, 27, (12), 1-16.
Doi : 10.1016/j.euroneuro.2017.10.037
184. HO W.S., HILEY C.R. : Vasodilator actions of abnormal cannabidiol in rat isolated small mesenteric artery, *British Journal of Pharmacology*, 2003, 138, 1320-1332.
185. HUDSON R., RENARD J., NORRIS C., RUSHLOW W.J., LAVIOLETTE S.R. : Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1–2 Phosphorylation, *Journal of Neuroscience*, 2019, 39, (44), 8762-8777.
Doi : 10.1523/JNEUROSCI.0708-19.2019

186. HUNDAL H. et al. : The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group, *Journal of Psychopharmacology*, 2018, 32, 3, 276-282.
187. HUNTSMAN R.J., TANG-WAI R., ALCORN J., VUONG S., ACTON B., CORLEY S., LAPRAIRIE R., LYON A.W., MEIER S. et al. : Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study, *Frontiers in Neurology*, 2019, Vol 10, Article 716, 1-9.
Doi : 10.3389/fneur.2019.00716
188. HURD Y.L., SPRIGGS S., ALISHAYEV J., WINKEL G., GURGOV K., KUDRICH C., OPRESCU A.M., SALSITZ E. : Cannabidiol for the Reduction of Clue-Induced Craving and Anxiety in Drug-Abstinent Individuals with Heroin Use Disorder : A Double-Blind Randomized Placebo-Controlled Trial, *AJP in Advance*, 2019, 1-12.
Doi : 10.1176/appi.ajp.2019.18101191
189. HUSSAIN S.A., ZHOU R., JACOBSON C. et al. : Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy : A potential role for infantile spasms and Lennox-Gastaut syndrome, *Epilepsy & Behaviour*, 2015, 47, 138-141.
190. IBEAS BIH C., CHEN T. NUNN A.V., BAZELOT M., DALLAS M., WHALLEY B.J. : Molecular Targets of Cannabidiol in Neurological Disorders, *Neurotherapeutics*, 2015, 12, 4, 699-730.
Doi : 10.1007/s13311-015-0377-3
191. IFFLAND K., GROTHENHERMEN F. : An Update on Safety and Side Effects of Cannabidiol : A Review of Clinical Data and Relevant Animal Studies, *Cannabis and Cannabinoid Research*, 2017, 2, (1), 139-154.
Doi : 10.1089/can.2016.0034
192. IGNATOWSKA-JANKOWSKA B., JANKOWSKI M.M., SWIERGIEL A.H. : Cannabidiol decreases body weight gain in rats : involvement of CB2 receptors, *Neuroscience Letters*, 2011, 490, (1), 82-84.
193. INGOLD F-R., SUEUR C., KAPLAN C. : Contribution à une exploration des propriétés thérapeutiques du cannabis, *Annales Médico-psychologiques*, 2015, 173, 5, 8 p.
Doi : 10.1016/j.amp.2015.04.001
194. INGOLD F-R., KAPLAN C., SUEUR C. : De cannabis bono, *Annales Médico-psychologiques*, 2020.
Doi : 10.1016/j.amp.2020.01.018
195. ISEGER T.A., BOSSONG M.G. : A systematic review of the antipsychotic properties of cannabidiol in humans, *Schizophrenia Research*, 2015, 162, (1-3), 153-161.
Doi : 10.1016/j.schres.2015.01.033
196. IUVONE T., ESPOSITO G., ESPOSITO R., SANTAMARIA R., Di ROSA M., IZZO A.A. : Neuroprotective effect of Cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells, *Journal of Neurochemistry*, 2004, 89, 1, 134-141.
197. JACOBS D.S., KOHUT S.J., JIANG S., NIKAS S.P., MAKRIYANNIS A., BERGMAN J. : Acute and chronic effects of cannabidiol on tetrahydrocannabinol (THC)-induced disruption in stop signal task performance, *Experimental and Clinical Psychopharmacology*, 2016, 24, (5), 320-330.

198. JADOON K.A., TAN G.D., O'SULLIVAN S.E. : A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study, *JCI Insight*, 2017, 2, (12), 11 p.
199. JIANG W. et al. : Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic and antidepressant-like effects, *Journal of Clinical Investigation*, 2005, 115, (11), 3104-3116.
200. JOHNSON J., CARTER A. : Can CBD help treat depression?, *Medical News Today*, Fri 29 March 2019.
<https://www.medicalnewstoday.com/articles/324846.php>
201. JONES N.A., GLYN S.E., AKIYAMA S. et al. : Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures, *Seizures*, 2012, 21, (5), 344-352.
202. JUKNAT A, KOZELA E, KAUSHANSKY N., MECHOULAM R., VOGEL Z. : Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol – studies in BV-2 microglia and encephalitogenic T cells, *Journal of Basic and Clinical Physiology and Pharmacology*, 2016, 27, (3), 289-96.
203. JUKNAT A, GAO F., COPPOLA G., VOGEL Z., KOZELA E. : miRNA expression profiles and molecular networks in resting and LPS-activated BV-2 microglia – Effect of cannabinoids, *PLoS One*, 2019, 1-25.
Doi : 10.1371/journal.pone.0212039
204. KAPLAN E.H., OFFERMANN E.A., SIEWERS J.W., COMI A.M. : Cannabidiol treatment for refractory seizures in Sturge-Weber syndrome, *Pediatric Neurology*, 2017, 71, 18-23.
205. KARIMI-HAGHIGHI S., HAGHPARAST A., BESHESTI S. : Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats, *Neuropsychopharmacology & Biological Psychiatry*, 2017.
Doi : 10.1016/j.pnpbp.2017.08.022
206. KARNIOL I.G., SHIRAKAWA I., KASINSKI N., PFEFERMAN A., CARLINI E.A. : Cannabidiol interferes with the effects of delta-9-tetrahydrocannabinol in man, *European Journal of Pharmacology*, 1974, 28, (1), 172-177.
207. KATSIDONI V., ANAGNOSTOU I., PANAGIS G. : Cannabidiol inhibits the reward-facilitating effect of morphine : involvement of 5-HT1A receptors in the dorsal raphe nucleus, *Addiction Biology*, 2013, 18, (2), 286-296.
208. KHAKSAR S., BIGDELI M.R. : Anti-excitotoxic effects of cannabidiol are partly mediated by enhancement of NCX2 and NCX3 expression in animal model of cerebral ischemia, *European Journal of Pharmacology*, 2016, 794, 270-279.
209. KHAN A.A., SHEKH-AHMAD T., KHALIL A. : Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model, *British Journal of Pharmacology*, 2018, 175, 2097-2115.
210. KHAN R., NAVED S., MIAN N., FIDA A., RAAFEY M.A., AEDMA K.K. : The therapeutic role of Cannabidiol in mental health : a systematic review, *Journal of Cannabis Research*, 2020, 2, 2.
Doi : 10.1186/s42238-019-0012-y
211. KHOURY J.M., NEVES M.C.L.D., ROQUE M.A.V., QUEIROZ D.A.B., CORRÊA de FREITAS A.A., de FATIMA Â., MOREIRA F.A., GARCIA F.D. : Is there a role for cannabidiol in psychiatry ?, *The World Journal of Biological Psychiatry*, 2019, 20, (2), 101-116.
Doi : 10.1080/15622975.2017.1285049

212. KIM J., CHOI J.Y. SEO J., CHOI I.S. : Neuroprotective Effect of Cannabidiol Against Hydrogen Peroxide in Hippocampal Neuron Culture, *Cannabis and Cannabinoid Research*, 2020, Volume X, Number X, 1-8.
Doi : 10.1089/can.2019.0102
213. KING K.M., MYERS A.M., SOROKA-MONZO A.J., TUMA R.F., TALLARIDA R.J. WALKER E.A., WARD S.J. : Single and combined effects of delta-(9)-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain, *British Journal of Pharmacology*, 2017, 174, (17), 2832-2841.
214. KIS B., IFRIM F.C., BUDA V., AVRAM S., PAVEL I.Z., ANTAL D., PAUNESCU V., DEHELEAN C.A., ARDELEAN F., DIACONEASA Z., SOICA C., DANCIU C. : Cannabidiol – from Plant to Human Body : A Promising Bioactive Molecule with Multi-Target Effects in Cancer, *International Journal of Molecular Sciences*, 2019, 20, 5905.
Doi : 10.3390/ijms20235905
215. KLEIN C., KARANGES E., SPIRO A., WONG A., SPENCER J., HUTYNH T., GUNASEKARAM et al. : Cannabidiol potentiates delta-(9)-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats, *Psychopharmacology (Berl)*, 2011, 218, (2), 443-457.
216. KLOFT L. : Review : The Efficacy of Cannabidiol (CBD) as Potential Antipsychotic Medication, *Maastricht Student Journal of Psychology and Neuroscience*, 2017, 6, 1, 118-132.
217. KOGAN N.M., MELAMED E., WASSERMAN E., RAPHAEL B., BREUER A., STOK K.S., SONDERGAARD R., ESCUDERO A.V et al. : Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts, *Journal of Bone and Mineral Research*, 2015, 30, (10), 1905-1913.
218. KOO C.M., KANG H.-C. : Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ?, *Journal of Epilepsy Research*, 2017, 7, 1, 1-5.
219. KOZELA E., KAUSHANSKY N, EILAM R., RIMMERMAN N., BEN-NUN A., JUKNAT A., VOGEL Z. : Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57Bl/6 mice, *British Journal of Pharmacology*, 2011, 163, (7), 1507-1519.
Doi : 10.1111/j.1476-5381.2011.01379.x
220. KOZELA E., JUKNAT A., KAUSHANSKY N, RIMMERMAN N., BEN-NUN A., VOGEL Z. : Cannabinoids decrease the Th17 inflammatory autoimmune phenotype, *Journal of Neuroimmune Pharmacology*, 2013, 8, (5), 1265-1276.
Doi : 10.1007/s11481-013-9493-1
221. KOZELA E., JUKNAT A., GAO F., KAUSHANSKY N, COPPOLA G., VOGEL Z. : Pathways and gene networks mediating the regulatory effects of cannabidiol, a non psychoactive cannabinoid, in autoimmune T cells, *Journal of Neuroinflammation*, 2016, 13, (1), Art 136.
Doi : 10.1186/s12974-016-0603-x
222. KOZELA E., JUKNAT A., VOGEL Z. : Modulation of Astrocyte Activity by Cannabidiol, a Non-psychoactive Cannabinoid, *International Journal of Molecular Sciences*, 2017, 18, 1669, 20 p.
Doi : 10.3390/ijms18081669

223. KOZELA E., KRAWCZYK M., KOS T., JUKNAT A., VOGEL Z., POPIK P. : Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats, *Molecular Neurobiology*, 2019, 15 p.
Doi : 10.1007/s12035-019-01833-2
224. KUCEROVA J., TABIOVA K., DRAGO F., MICALE V. : Therapeutic potential of cannabinoids in schizophrenia, *Recent Patents on CNS Drug Discovery*, 2014, 9, (1), 13-25.
Doi : 10.2174/1574889809666140307115532
225. LAFUENTE H., ALVAREZ F.J., PAZOS M.R. et al : Cannabidiol reduces brain damage and improves functional recovery after acute hypoxia-ischemia in newborn pigs, *Pediatric Research*, 2011, 70, 272-277.
226. LAFUENTE H., PAZOS M.R., ALVAREZ F.J. et al : Effects of Cannabidiol and Hypothermia on Short-Term Brain Damage in New-Born Piglets after Acute Hypoxia-Ischemia, *Frontiers in Neuroscience*, 2016, 10, Article 323.
Doi : 10.3389/fnins.2016.00323
227. LAPRAIRIE R.B., BAGHER A.M., KELLY M.E., DENOVAN-WRIGHT E.M. : Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor, *British Journal of Pharmacology*, 2015, 172, 4790– 4805.
228. LASTRES-BECKER I., MOLINA-HOLGADO F., RAMOS J.A., MECHOULAM R., FERNANDEZ-RUIZ J. : Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro : relevance to Parkinson's disease, *Neurobiology of Disease*, 2005, 19, (1-2), 96-107.
229. LATTANZI S., BRIGO F., TRINKA E., ZACCARA G., CAGNETTI C., Del GIOVANE C., SILVESTRINI M. : Efficacy and Safety of Cannabidiol in Epilepsy : A Systematic Review and Meta-Analysis, *CNS Drugs*, 2018, 78, 17.
Doi : 10.1007/s40265-018-0992-5
230. LATTANZI S., BRIGO F., CAGNETTI C., TRINKA E., SILVESTRINI M. : Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome : A Systematic Review and Meta-Analysis, *CNS Drugs*, 2018, 32, (10), 905-916.
Doi : 10.1007/s40263-018-0558-9
231. LAUN A.S., SONG Z.H. : GPR3 and GPR6, novel molecular targets for cannabidiol, *Biochemical and Biophysical Research Communications*, 2017, 490, (1), 17-21.
Doi : 10.1016/j.bbrc.2017.05.165
232. LAUX L.C., BEBIN E.M., CHECKETTS D. et al. : Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome : expanded access program results, *Epilepsy Research*, 2019, 154, 13-20.
233. LEE C.-Y., WEY S.-P., LIAO M.-H., HSU W.-L., WU H.-Y., JAN T.R. : A comparative study on cannabidiol-induced apoptosis in murine thymocytes and EL-4 thymoma cells, *International Immunopharmacology*, 2008, 8, (5), 732-740.
Doi : 10.1016/j.intimp.2008.01.018
234. LEE W.S., ERDELYI K., MATYAS C., MUKHOPADHYAY P., MECHOULAM R. et al. : Cannabidiol limits Tcell-mediated chronic autoimmune myocarditis, implications to autoimmune disorders and organ transplantation, *Molecular Medicine*, 2016, 22, 136-146.
Doi : 10.2119/molmed.2016.00007

235. LEHMANN C., FISHER N.B., TUGWELL B., SZCZESNIAK, KELLY M., ZHOU J. : Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes, *Clinical Hemorheology and Microcirculation*, 2016, 64, (4), 655-662.
Doi : 10.3233/ch-168021
236. LEO A., RUSSO E., ELIA M. : Cannabidiol and epilepsy : Rationale and therapeutic potential, *Pharmacological Research*, 2016, 107, 85-92.
237. LEVIN R., PERES F.F., ALMEIDA V., CALZAVARA M.B., ZUARDI A.W., HALLAK J.E.C., CRIPPA J.A.S., ABILIO V.C. : Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia : the SHR strain, *Frontiers in Pharmacology*, 2014, 5, article 10.Doi : 10.3389/fphar.2014.00010
238. LEWEKE F.M., SCHNEIDER U., RADWAN M., SCHMIDT E., EMRICH H.M. : Different effects of nabilone and cannabidiol on binocular depth inversion in man, *Pharmacology Biochemistry & Behavior*, 2000, 66, 175-181.
239. LEWEKE F.M. et al. : Cannabidiol as an antipsychotic agent, *European Psychiatry*, 2007, 22, 1.
240. LEWEKE F.M. : Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis (CBD-CT1), essai NCT00628290, University of Cologne, Germany, 2008.
241. LEWEKE F.M., KOETHE D., PAHLISCH F. et al. : Antipsychotic effects of cannabidiol, *European Psychiatry*, 2009, 24, suppl 1, 207,
242. LEWEKE F.M., PIOMELLI D., PAHLISCH F., MUHL D., GERTH C.W., HOYER C., KLOSTERKÖTTER J., HELLMICH M., KOETHE D. : Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, *Translational Psychiatry*, 2012, 2, (3), e94.
Doi : 10.1038/tp.2012.15
243. LEWEKE F.M., MUELLER J.K., LANGE B., ROHLEDER C. : Therapeutic potential of cannabinoids in psychosis, *Biological Psychiatry*, 2016, 79, 7, 604-612.
Doi : 10.1016/j.biopsych.2015.11.018
244. LEWEKE F.M., KOETHE D., GERTH C.W., NOLDEN B.M. et al. : Cannabidiol as an antipsychotic : a double-blind, controlled clinical trial of cannabidiol versus amisulpride in acute schizophrenia, *15th Annual Symposium on Cannabinoids*, Clearwater, Florida, Cannabinoid Research Society.
245. LEWEKE F.M., MUELLER J.K., LANGE B., FRITZE S., TOPOR C.E., KOETHE D., ROHLEDER C. : Role of the endocannabinoid System in the Pathophysiology of Scizophrenia : Implications for Pharmacological Intervention, *CNS Drug*, 2018, 32, 7, 605-619.
Doi : 10.1007/s40263-018-0539-z
246. LI K., FENG J.Y., LI Y.Y., YUECE B. et al. : Anti-inflammatory role of cannabidiol and O-1602 in cerulean-induced acute pancreatitis in mice, *Pancreas*, 2013, 42, (1), 123-129.
247. LIGRESTI A., MORIELLO A.S., STAROWICZ K., MATIAS I., PISANTI S., De PETROCELLIS L., LAEZZA C., PORTELLA G., BIFULCO M., Di MARZO V.: Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma, *Journal of Pharmacology and Experimental Therapeutics*, 2006, 318, (3), 1375-1387.
Doi : 10.1124/jpet.106.105247
248. LINARES I.M., ZUARDI A.W., PEREIRA L.C., QUEIROZ R.H., MECHOULAM R., GUIMARAES F.S., CRIPPA J.A. : Cannabidiol presents an inverted U-shaped dose-

response curve in a simulated public speaking test, *Brazilian Journal of Psychiatry*, 2018, 6 p.

Doi : 10.1590/1516-4446-2017-0015

249. LINARES I.M.P., GUIMARAES F.S., ECCELLI A., CRIPPA A.C.S., ZUARDI A.W., SOUZA J.D.S., HALLAK J.E., CRIPPA J.A.S. : No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects : A Randomized, Double-Blind, Placebo-Controlled, Crossover Study, *Frontiers in Pharmacology*, 2018, Vol 9, Article 315, 1-8.
Doi : 10.3389/fphar.2018.00315
250. LINGE R., JIMENEZ-SANCHEZ L., CAMPA L., PILAR-CUELLAR F., VIDAL R., PAZOS A., ADELL A., DIAZ A. : Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission : role of 5-HT-1A receptors, *Neuropharmacology*, 2016, 103, 16-26.
Doi : 10.1016/j.neuropharm.2015.12.017
251. LIOU G., EL-RHEMESSY A., IBRAHIM A., CALDWELL R., KHALIFA Y., GUNES A., NUSSBAUM J. : Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy : A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development, *Current Pharmacogenomics Person Med*, 2009, 7, (3), 215-222.
252. LIPPIELLO P., BALESTRINI S., CITRARO R., RUSSO E. et al. : From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We, *Current Pharmaceutical Design*, 2016, 22, 42, 6426-6433.
253. LIPUT D.J., HAMMEL D.C., STINCHCOMB A.L., NIXON K. : Transdermal Delivery of Cannabidiol Attenuates Binge Alcohol-Induced Neurodegeneration in a rodent Model of an Alcohol Use Disorder, *Pharmacology, Biochemistry and Behavior*, 2013, 111, 120-127.
Doi : 10.1016/j.pbb.2013.08.013
254. LONG L.E., MALONE D.T., TAYLOR D.A. : Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice, *Neuropsychopharmacology*, 2006, 31, 795-803.
255. LONG L.E., CHESWORTH R., HUANG X.-F., McGREGOR I.S., ARNOLD J.C., KARL T. : A behavioural comparison of acute and chronic delta-9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice, *International Journal of Neuropsychology*, 2010, 13, 861-876.
Doi : 10.1017/S1461145709990605
256. LONGO D.L., FRIEDMAN D., DEVINSKY O. : Cannabinoids in the treatment of epilepsy, *New England Journal of Medicine*, 2015, 373 1048-1058.
257. LUKHELE S.T., MOTADI L.R. : Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells, *BMC Complementary and Alternative Medicine*, 2016, 16, (1), 335.
Doi : 10.1186/s12906-016-1280-0.
258. MABOU TAGNE A.M., PACCHETTI B., SODERGREN M., COSENTINO M., MARINO F. : Cannabidiol for Viral Diseases : Hype or Hope ?, *Cannabis and Cannabinoid Research*, 2020, 1-11.
Doi : 10.1089/can.2019.0060
259. MADRAS B.H., HASBI A., JACOBS D., KOHUT S., BERGMAN J., GEORGE S. : Dramatic increase of dopamine D1-D2 receptor heteromers by tetrahydrocannabinol (THC) in primate caudate nucleus is attenuated by

cannabidiol (CBD), *American College for Neuropsychopharmacology 55th Annual Meeting, Hollwood, Florida*, 3-8 December 2016, Poster M245.

260. MAHMUD A., GALLANT S., SEDKI F., D'CUNHA T., SHALEV U. : Effects of an acute cannabidiol treatment on cocaine self-administration and cue-induced cocaine seeking in male rats, *Journal of Psychopharmacology*, 2017, 31, (1), 96-104.
Doi : 10.1177/0269881116667706
261. MALFAIT A.M., GALLILY R., SUMARIWALLA P.F., MALIK A.S., ANDREAKOS E., MECHOULAM R., FELDMANN M. : The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritis therapeutic in murine collagen-induced arthritis, *PNAS, Proceedings of the National Academy of Sciences USA*, 2000, 97, (17), 9561-9566.
Doi : 10.1073/pnas.160105897
262. MANDOLINI G.M., LAZZARETTI M., PIGONI A., OLDANI L., DELVECCHIO G., BRAMBILLA P. : Pharmacological properties of cannabidiol in the treatment of psychiatric disorders : a critical overview, *Epidemiology and Psychiatric Sciences*, 2018, 27, (4) 327-335.
Doi : 10.1017/S2045796018000239
263. MANINI A.F., YIANNOULOS G., BERGAMASCHI M.M., HERNANDEZ S., OLMEDO R., BARNES A.J., et al. : Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly with Intravenous Fentanyl in Humans, *Journal of Addiction Medicine*, 2015, 9, (3), 204-210.
Doi : 10.1097/ADM.0000000000000118
264. MANNUCCI C., NAVARRA M., CALAPAI F. et al. : Neurological Aspects of Medical Use of cannabidiol, *CNS & Neurological Disorders – Drug Targets*, 2017, 16, 13 pp.
265. MANSEAU M.W., GOFF D.C. : Cannabinoids and Schizophrenia : Risks and Therapeutic Potential, *Neurotherapeutics*, 2015, 12, 816-824.
Doi : 10.1007/s13311-015-0382-6
266. MARCU J.P., CHRISTIAN R.T., LAU D., ZIELINSKI A.J., HOROWITZ M.P., LEE J. et al. : Cannabidiol enhances the inhibitory effects of delta-9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival, *Molecular Cancer Therapeutics*, 2010, 9, (1), 180-189.
Doi : 10.1158/1535-7163.MCT-09-0407
267. MARKOS J.R., HARRIS H.M., GUL W., EISOHLY M.A., SUFKA K.J. : Effects of Cannabidiol on Morphine Conditioned Place Preference in Mice, *Planta Medica*, 2018, 84, (4), 221-224.
Doi : 10.1055/s-0043-117838
268. MARTIN A.R., CONSROE P., SINGH V., MECHOULAM R. et al. : Structure-anticonvulsant activity relationships of cannabidiol analogs, *NIDA Research Monography*, 1987, 79, 48-58.
269. MARTIN-MORENO et al. : Cannabidiol and Other Cannabinoids Reduce Microglial Activation In Vitro and in Vivo : Relevance to Alzheimer's Disease, *Molecular Pharmacology*, 2011, 79, 6, 964-973.
270. MARTIN-SANTOS R., CRIPPA J.A., BATALLA A., BHATTACHARYYA S., ATAKAN Z., BORGWARDT S., ALLEN P., SEAL M., LANGOHR K., FARR2 M., ZUARDI A.W., McGuire P.K. : Acute effects of a single, oral dose of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers, *Current Pharmaceutical Design*, 2012, 18, (32), 4966-4979.
Doi : 10.2174/138161212802884780

271. MASSI P., SOLINAS M., CINQUINA V., PAROLARO D.: Cannabidiol as Potential anticancer drug, *British Journal of Clinical Pharmacology*, 2013, 75, 2, 303-312.
272. MATHERN G.W., BENINSIG L., NEHLIG A. : Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients : result of Epilepsia's survey, *Epilepsia*, 2015, 56, 1-6.
273. McALLISTER S.D., CHRISTIAN R.T., HOROWITZ M.P., GARCIA A., DESPREZ P.-Y. : Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells, *Molecular Cancer Therapeutics*, 2007, 6, (11), 2921-2927.
274. McALLISTER S.D., MURASE R., CHRISTIAN R.T., LAU D., ZIELINSKI A.J., ALLISON J., ALMANZA C., PAKDEL A., LEE J., LIMBAD C., LIU Y., DEBS R.J., MOORE D.H., DESPREZ P.-Y. : Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis, *Breast Cancer Research Treatment*, 2011, 129, (1), 37-47.
Doi : 10.1007/s10549-010-1177-4
275. McALLISTER S.D., SOROCEANU L., DESPREZ P.-Y. : The antitumor activity of plant-derived non-psychoactive cannabinoids, *Journal of Neuroimmune Pharmacology*, 2015, 10, (2), 255-267.
Doi : 10.1007/s11481-015-9608-y
276. MCCOY B., WANG L., ZAK M. et al. : A prospective open-label trial of a CBD / THC cannabis oil in Dravet syndrome, *Annals of Clinical and Translational Neurology*, 2018, 5, 1077-1088.
Doi : 10.1002/acn3.621
277. McGUIRE P., ROBSON P., CUBALA W.J., VASILE D., MORRISON P.D., WRIGHT S. : A double-blind, randomised, placebo-controlled, parallel group trial of cannabidiol as adjunctive therapy in the first line treatment of schizophrenia or related psychotic disorder, *Schizophrenia International Research Society (SIRS) Biannual Meeting*. Florence, Italy, 2016.
http://www.medscape.com/viewarticle/862312#vp_2.
278. McGUIRE P., ROBSON P., CUBALA W.J., VASILE D., MORRISON P.D., BARRON R., TAYLOR A., WRIGHT S. : Cannabidiol (CBD) as an adjunctive Therapy in Schizophrenia : A multicenter Randomized Controlled Trial, *American Journal of Psychiatry*, 2018, 175, 3, 225-231.
Doi : 10.1176/appi.ajp.2017.17030325
279. McGUIRE P., ROBSON P. et al. : A Randomized Controlled Trial of Cannabidiol in Schizophrenia, *Sixth Biennial SIRS Conference*, 2018.
280. MCKALLIP R.J., JIA W., SCHLOMER J., WARREN J.W., NAGARKATTI P.S., NAGARKATTI M. : Cannabidiol-induced apoptosis in human leukemia cells : A novel role of cannabidiol in the regulation of p22phox and Nox4 expression, *Molecular Pharmacology*, 2006, 70, (3), 897-908.
281. McLOUGHLIN B.C., PUSHPA-RAJAH J.A., GILLIES D., RATHBONE J., VARIEND H., KALAKOUTI E., KYPRIANOU K. : Cannabis and schizophrenia (Review), *The Cochrane Collaboration, Published by John Wiley & Sons, Ltd*, 2014, 10, Article n° CD004837
Doi : 10.1002/14651858.CD004837.pub3
282. MCPARTLAND J.M., DUNCAN M., Di MARZO V., PERTWEE R.G. : Are Cannabidiol and delta-9-tetrahydrocannabivarin negative modulators of the

- endocannabinoid system ? A systematic review, *British Journal of Pharmacology*, 2015, 172, 737-753.
Doi : 10.1111/bph.12944
283. MECHA M., MECHOULAM R. et al. : Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress, *Cell Death and Disease*, 2012, 3.
284. MECHA M., FELIU A., INIGOL P.M., MESTRE L., CARRILLO-SALINAS F.J., GUAZA C. : Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A_{2A} receptors, *Neurobiology of Disease*, 2013, 59, 141-150.
Doi : 10.1016/j.nbd.2013.06.016
285. MECHOULAM R., HANUS L. : The cannabinoids : an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection, *Pain Research Management*, 2001, 6, (2), 67-73.
286. MECHOULAM R., PARKER L.A., GALLILY R. : Cannabidiol : an overview of some pharmacological aspects, *Journal of Clinical Pharmacology*, 2002, 42, 11S-19S.
287. MECHOULAM R., PETERS M., MURILLO-RODRIGUEZ E., HANUS L.O. : Cannabidiol – Recent Advances, *Chemistry & Biodiversity*, 2007, 4, 8, 1678-1692.
Doi : 10.1002/cbdv.200790147
288. MEIER U., DUSSY F., SCHEURER E., MERCER-CHALMERS-BENDER K., HANGARTNER S. : Cannabinoid Concentrations in Blood and Urine after Smoking Cannabidiol Joints, *Forensic Science International*, 2018, 291, 1-15.
Doi : 10.1016/j.forsciint.2018.08.009
289. MILIAN L., MATA M., ALCACER J., OLIVER M., SANCHO-TELLO M., MARTIN de LLANO J.J., CAMPS C., GALBIS J., CARRETERO J., CARDÀ C. : Cannabinoid receptor expression in non small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro, *PLoS One*, 2020, 1-17.
Doi : 10.1371/journal.pone.0228909
290. MILLAR S.A., STONE N.L., YATES A.S., O'SULLIVAN S.E. : A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans, *Frontiers in Pharmacology*, 26 November 2018.
Doi : 10.3389/fphar.2018.01365
291. MILLER I., PERRY M.S., SANETO R.P. et al. : Cannabidiol (CBD, 10 and 20 mg/kg/day) significantly reduces convulsive seizure frequency in children and adolescents with Dravet syndrome (DS) : Results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE2), Presented at « 71st American Academy of Neurology Annual Meeting », May 4-10, 2019, Philadelphia, PA, Emerging science abstract.
292. MITELPUNKT A., KRAMER U., HAUSMAN-KEDEM M. et al. : The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: a phase II, open-label, single-center study, *Epilepsy & Behavior*, 2019, 98, 233-237.
293. MOHAMMED N., CEPRIAN M., JIMENEZ L., PAZOS M.R., MARTINEZ-ORGADO J. : Neuroprotective Effects of Cannabidiol in Hypoxic Ischemic Insult. The Therapeutic Window in Newborn Mice, *CNS and Neurological Disorders – Drug Targets*, 2017, 16, (1), 35-43.

294. MOREIRA F.A., AGUIAR D.C., GUIMARÃES F.S. : Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test, *Progress in Neuro-psychopharmacology & Biological Psychiatry*, 2006, 30, (8), 1466-1471.
Doi : 10.1016/j.pnpbp.2006.06.004
295. MORGAN C.J.A., CURRAN V. : Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis, *British Journal of Psychiatry*, 2008, 192, 306-307.
Doi : 10.1192/bjp.bp.107.046649
296. MORGAN C.J., FREEMAN T.P., SCHAFER G.L., CURRAN H.V. : Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis, *Neuropsycho-pharmacology*, 2010, 35, 9, 1879-1885.
297. MORGAN C.J., SCHAFER G., FREEMAN T.P., CURRAN H.V.: Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis : naturalistic study, *British Journal of Psychiatry*, 2010, 197, 285-290.
298. MORGAN C.J., GARDENER C., SCHAFER G. et al. : Sub-chronic impact of cannabinoids in street cannabis on cognition, psychoticlike symptoms and psychological well-being, *Psychological Medicine*, 2012, 42, 391-400.
299. MORGAN C.J., DAS R.K., JOYE A., CURRAN H.V., KAMBOJ S.K. : Cannabidiol reduces cigarette consumption in tobacco smokers : preliminary findings, *Addiction Behaviors*, 2013, 38, (9), 2433-2436.
300. MORGAN C.J.A., FREEMAN T.P., HINDOCHA C., SCHAFER G., GARDNER C., CURRAN H.V. : Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function, *Translational Psychiatry*, 2018, 8, 181
Doi : 10.1038/s41398-018-0191-x
301. MORI M.A., MEYER E., SOARES L.M., MILANI H., GUIMARAES F.S., de OLIVEIRA R.M. : Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia, *Progress in Neuropsychopharmacology and Biological Psychiatry*, 2017, 75, 94-105.
302. MORTIMER T.L., MABIN T., ENGELBRECHT A.-M. : Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting, *Future Oncology*, 2019.
Doi : 10.2217/fon-2018-0530
303. MUKHOPADHYAY P., RAJESH M., HORVATH B., BATKAI S., PARK O., TANCHIAN G., GAO R.Y., PATEL V., WINK D.A., LIAUDET L., HASKO G., MECHOULAM R., PACHER P. : Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death, *Free Radical and Biology and Medicine*, 2011, 50, (10), 1368-1381.
304. MURILLO-RODRIGUEZ E., LILLAN-ALDACO D., PALOMERO-RIVERO M., MECHOULAM R., DRUCKER-COLIN R. : Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats, *FEBS Letters (Federation of European Biochemical Societies)*, 2006, 580, 4337-4345.
305. MURILLO-RODRÍGUEZ E., SARRO-RAMÍREZ A., SÁNCHEZ D., MIJANGOS-MORENO S., TEJEDA-PADRÓN A., POOT-AKÉ A., GUZMÁN K., PACHECO-PANTOJA E., ARIAS-CARRIÓN O. : Potential Effects of Cannabidiol as a Wake-Promoting Agent, *Current Neuropharmacology*, 2014, 12, 269-272
306. NABISSI M., MORELLI M.B., AMANTINI C., LIBERATI S., SANTONI M., RICCI-VITIANI L., PALLINI R., SANTONI G. : Cannabidiol stimulates Aml-1a-dependent

- glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner, *International Journal of Cancer*, 2015, 137, (8), 1855-1869.
307. NABISSI M., MORELLI M.B., OFFIDANI M., AMANTINI C., GENTILI S., SORIANI A., CARDINALI C., LEONI P., SANTONI G. : Cannabinoids synergyze with carfilzomib, reducing multiple myeloma cells viability and migration, *Oncotarget*, 2016, 7, (47), 77543-77557.
308. NADULSKI T., PRAGST F., WEINBERG G., ROSER P., SCHNELLE M., FRONK E.-M., STADELMANN A.M. : Randomized, Double-Blind, Placebo-Controlled Study About the Effects of Cannabidiol (CBD) on the Pharmacokinetics of delta-9-Tetrahydrocannabinol (THC) After Oral Application of THC Verses Standardized Cannabis Extract, *Therapeutic Drug Monitoring*, 2005, 27, (6), 799-810.
309. NAFTALI T., MECHOULAM R., MARII A., GABAY G., STEIN A., BRONSHTAIN M., LAISH I., BENJAMINOV F., KONIKOFF F.M. : Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn'S Disease, a Randomized Controlled Trial, *Digestive Diseases and Sciences*, 2017, 62, 1615-1620.
Doi : 10.1007/s10620-017-4540-z
310. NAGAO M., NAKANO Y., TAJIMA M., SUGIYAMA E., SATO V.H., INADA M., SATO H. : Nonlinear Disposition and Metabolic Interactions of Cannabidiol Through CYP3A Inhibition In Vivo in Rats, *Cannabis and Cannabinoid Research*, 2020, Volume X, Number X, 1-8.
Doi : 10.1089/can.2019.0098
311. NAGAYAMA T.et al. : Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures, *Journal of Neurosciences*, 1999, 19, 2987-2995.
312. NAHLER J. : Co-medication with cannabidiol may slow down the progression of motor neuron disease : a case reports, *Journal of General Practice (Los Angeles)*, 2017, 5, 4.
313. NAHLER G., GROTHENHERMEN F., ZUARDI A.W., CRIPPA J.A.S. : A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans, *Cannabis and Cannabinoid Research*, 2017, 2, (1), 81-86.
Doi : 10.1089/can.2017.0009
314. NAKANO Y., TAJIMA M., SUGIYAMA E., SATO V.H., SATO H. : Development of a Novel Nanoemulsion Formulation to Improve Intestinal Absorption of Cannabidiol, *Medical Cannabis and Cannabinoids*, 2019, 2, 35-42.
Doi : 10.1159/000497361
315. NAVARRETE F., ARACIL-FERNANDEZ A., MANZANARES J. : Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal, *British Journal of Pharmacology*, 2018 175, (13), 2676-2688.
Doi : 10.1111/bph.14226
316. NAZARIO L.R., ANTONIOLI R Jr, CAPIOTTI K.M., HALLAK J.E., ZUARDI A.W., CRIPPA J.A., BONAN C.D., da SILVA R.S. : Coffeine protects against memory los induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (*Danio rerio*), *Pharmacology Biochemistry and Behavior*, 2015, 135, 210-216.col
317. NEELAKANTAN H., TALLARIDA R.J., REICHENBACH Z.W., TUMA R.F., WARD S.J., WALKER E.A. : Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice, *Behavioural Pharmacology*, 2015, 26, (3), 304-314.

Doi : 10.1097/FBP.0000000000000119

318. NICHOLS J.M., KAPLAN B.L.F. : Immune Responses Regulated by Cannabidiol, *Cannabis and Cannabinoid Research*, 2019.
- Doi : 10.1089/can.2018.0073
319. NICHOLSON A.M., TURNER C., STONE B.M., ROBSON P.J. : Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults, *Journal of Clinical Psychopharmacology*, 2004, 24, (3), 305-313.
- Doi : 10.1097/jcp.0000125688.05091.8f
320. NIELSEN S., GERMANOS R., WEIER M. et al. : The use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis : a systematic Review of Reviews, *Current Neurology and Neuroscience Reports*, 2018, 18, 8, 12 pp.
321. NIESINK R.J.M., Van LAAR M.W. et al. : Does cannabidiol protect against adverse psychological effects of THC ?, *Frontiers in Psychiatry*, 2013, 4, 130.
- Doi : 10.3389/fpsyg.2013.00130
322. NITECKA-BUCHTA A., NOWAK-WACHOL A., WACHOL K., WALCZYNNSKA-DRAGON K., OLCZYK P., BATORYNA O., KEMPA W., BARON S. : Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD : A Randomized, Double-Blind Trial, *Journal of Clinical Medicine*, 2019, 8, 1886, 1-17.
- Doi : 10.3390/jcm8111886
323. O'BRIEN T., BERKOVIC S.F., FRENCH J. et al. : Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults, Presented at « *American Epilepsy Society Annual Meeting* », Washington, DC, December 1-5, 2017, Poster 2.428.
324. O'BRIEN T., BERKOVIC S.F., FRENCH J. et al. : Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults, Presented at « *American Epilepsy Society Annual Meeting* », New Orleans, LA, November 30-December 4, 2018, Poster.
325. OHRI A., DOUGHERTY M. : Exploring the Use of Cannabidiol in Epilepsy Management, *Practical Neurology*, 2016, July/August, 48-50.
326. OLAH A., MARKOVICS A., SZABO-PAPP J., SZABO P.T., STOTT C., ZOUBOULIS C.C., BIRO T. : Differential effectiveness of selected non-psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrheic skin and acne treatment, *Experimental Dermatology*, 2016, 25, (9), 701-707.
327. OLAH A., TOTH B.I., BORBIRO I., SUGAWARA K., SZOLLOSI A.G. et al. : Cannabidiol exerts sebostatic and anti-inflammatory effects on human sebocytes, *Journal of Clinical Investigation*, 2014, 124, (9), 3713-3724
328. OLDHAM M., SULLIVAN J., SINGHAL N., TILTON N., CILIO M. : Long-term efficacy and tolerability of add-on cannabidiol for drug-resistant pediatric epilepsy, in « *Proceedings of the American Epilepsy Society Annual Meeting* », 2015, December 4-8, Philadelphia, P.A, Abstr 2.296, American Epilepsy Society, Chicago, IL.
329. O'NEILL A., WILSON R., BLEST-HOPLEY G., ANNIBALE L., COLIZZI M., BRAMMER M., GIAMPIETRO V., BHATTACHARYYA S. : Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis, *Psychological Medicine*, 2020, 1-11.
- Doi : 10.1017/S0033291719003519

330. OSBORN A.L., SOLOWIJ N., BABIC I., HUANG X.F., WESTON-GREEN K. : Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (Poly I:C) Rat Model, *Neuropsychopharmacology*, 2017, 42, (7), 1447-1457.
331. OSBORN A.L., SOLOWIJ N., WESTON-GREEN K. : A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia, *Neuroscience & Behavioral Reviews*, 2017, 72, 310-324.
Doi : 10.1016/j.neubiorev.2016.11.012
332. PAGANO E., CAPASSO R., PISCITELLI F., ROMANO B., PARISI O.A., FINIZIO S., LAURITANO A., Di MARZO V. et al. : An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse, *Frontiers in Pharmacology*, 2016, Vol 7, Article 341.
Doi : 10.3389/fphar.2016.00341
333. PARKER L.A., BURTON P., SORGE R.E., YAKIWCHUK C., MECHOULAM R. : Effect of low doses of Delta-9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats, *Psychopharmacology (Berl)*, 2004, 175, 3, 360-366
Doi : 10.1007/s00213-004-1825-7
334. PARKER L.A., ROCK E.M., LIMEBEER C.L. : Regulation of nausea and vomiting by cannabinoids, *British Journal of Pharmacology*, 2011, 163, (7), 1411-1422.
335. PAROLARO D., ZAMBERLETTI E., RUBINO T. : Cannabidiol / Phyto-cannabinoids : a new opportunity for schizophrenia treatment ?, in PERTWEE R.G. editor : "Handbook of Cannabis", Oxford University Press, United Kingdom, 2016, 526-537.
336. PARRAY H.A., YUN J.W. : Cannabidiol promotes browning in 3T3-L1 adipocytes, *Molecular and Cellular Biochemistry*, 2016, 416, (1-2), 131-139.
337. PATEL R.R., BARBOSA C., BRUSTOVETSKY T., BRUSTOVETSKY N., CUMMINS T.R. : Aberrant epilepsy-associated mutant Nav 1.6 sodium channel activity can be targeted with cannabidiol, *Brain*, 2016, 139, (Pt 8), 2164-2181.
338. PATRA P.H., BARKER-HALISKI M., WHITE H.S., WHALLEY B.J., GLYN S., SANDHU H., JONES N., BAZELOT M., WILLIAMS C.M., McNEISH A.J. : Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models, *Epilepsia*, 2018, 1-12.
Doi : 10.1111/epi.14629
339. PAZOS M.R., MOHAMMED N., LAFUENTE H. et al : Mechanisms of cannabidiol neuroprotection in hypoxi-ischemic newborn pigs : role of 5HT(1A) and CB2 receptors, *Neuropharmacology*, 2013, 71, 282-291.
340. PELLATI F., BORGONETTI V., BIAGI M., BENVENUTI S., CORSI L. : Cannabis sativa L. and Non-psychoactive Cannabinoids : Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer, *Hindawi, BioMed Research International*, 2018, Vol 2018, Article ID 1691428, 15 pages.
Doi : 10.1155/2018/1691428
341. PERES F.F., DIANA M.C., SUIAMA M.A., JUSTI V., ALMEIDA V., BRESSAN R.A., ZUARDI A.W., HALLAK J.E.C., CRIPPA J.A., ABILIO V.C. : Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia, *Schizophrenia Research*, 2016, 172, (1-3), 220-221.

342. PERES F.F., DIANA M.C., LEVIN R., SUIAMA M.A., ALMEIDA V., VENDRAMINI A.M., SANTOS C.M., ZUARDI A.W., HALLAK J.E.C., CRIPPA J.A., ABILIO V.C. : Cannabidiol Administered During Peri-adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia, *Frontiers in Pharmacology*, 2018, 9, article 901.
Doi : 10.3389/fphar.2018.00901
343. PEREZ M., BENITEZ S.U. CARTAROZZI L.P., del BEL E., GUIMARAES F.S., OLIVEIRA A.L. : Neuroprotection and reduction of glial reaction by cannabidiol treatment after sciatic nerve transection in neonatal rats, *European Journal of Neuroscience*, 2013, 1_10.
Doi : 10.1111/ejn.12341
344. PEREZ M., CARTAROZZI L.P., CHIAROTTO B.G., ALVES de OLIVEIRA S., GUIMARAES F.S., RODRIGUES de OLIVEIRA A.L. : Neuronal preservation and reactive gliosis attenuation following neonatal sciatic nerve axotomy by a fluorinated cannabidiol derivative, *Neuropharmacology*, 2018.
Doi : 10.1016/j.neuropharm.2018.08.009
345. PERTWEE R.G. : Cannabidiol as a potential medicine, in "Cannabinoids as Therapeutics", ed. MECHOULAM R., Basel, Birkhauser Verlag, 2005, 47-65.
346. PERTWEE R.G. : The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta 9-tetrahydrocannabinol, Cannabidiol, and delta 9-tetrahydronabivarin, *British Journal of Pharmacology*, 2008, 153, 199-215.
347. PERTWEE R. : Cannabinoids and multiple sclerosis, *Pharmacology & Therapeutics*, 2002, 95, 2, 165-174.
348. PERTWEE R.G. editor : Handbook of Cannabis, Oxford University Press, United Kingdom, 2016.
349. PETITET F., JEANTAUD B., REIBAUD M., IMPERATO A., DUBROEUCQ M.C. : complex pharmacology of natural cannabinoids : evidence for partial agonist activity of delta-9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors, *Life Science*, 1998, 63, (1), PL 1-6.
350. PIETRAFUSA N., FERRETTI A., TRIVISANO M. et al. : Purified cannabidiol for treatment of refractory epilepsies in pediatric patients with developmental and epileptic encephalopathy, *Paediatric Drugs*, 2019, 21, 283-290.
Doi : 10.1007/s40272-019-00341-x
351. PISANTI S., MALFITANO A.M., CIAGLIA E., LAMBERTI A., RANIERI R., CUOMO G., ABATE M., FAGGIANA G. et al : Cannabidiol : State of the art and new challenges for therapeutic applications, *Pharmacology & Therapeutics*, 2017.
Doi : 10.1016/j.pharmthera.2017.02.041
352. PORTER B.E., JACOBSON C. : Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy, *Epilepsy & Behavior*, 2013, 29, 3, 574-577.
353. PRUD'HOMME M., CATA R., JUTRAS-ASWAD D. : Cannabidiol as an intervention for addictive behaviors : a systematic review of evidence, *Substance Abuse : Research and Treatment*, 2015, 9, 33-38.
Doi : 10.4137/SART.S25081
354. RAHIMI A., FAIZI M., TALEBI F., NOORBAKHS F., KAHRIKI F., NADERI N. : Interaction between the protective effects of cannabidiol and palmitoyl-ethanolamide in experimental model of multiple sclerosis in C57BL/6 mice, *Neuroscience*, 2015, 290, 279-287.
Doi : 10.1016/j.neuroscience.2015.01.030

355. RAHN B. : Using CBD to Tame a Cannabis High? Small Doses May Have the Opposite Effect, *Science & Tech*, February 28, 2019.
<https://www.leafly.com/news/science-tech/how-cbd-dose-affects-cannabis-effects/print/>
356. RAJAN T.S., GIACOPPO S., IORI R., De NICOLA G.R., GRASSI G., POLLASTRO F. et al. : Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages, *Fitoterapia*, 2016, 112, 104–115.
Doi : 10.1016/j.fitote.2016.05.008
357. RAJAN T.S., SCIONTI D., DIOMEDE F., GRASSI G., POLLASTRO F. et al. : Gingival Stromal Cells as an In vitro Model : Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis, *Journal of Cellular Biochemistry*, 2017, 118, (4), 819-828.
358. RAJARAMAN R.R., SANKAR R., HUSSAIN S.A. : Successful use of pure cannabidiol for the treatment of super-refractory status epilepticus, *Epilepsy & Behavior Case Reports*, 2018, 10, 141-144.
Doi : 10.1016/j.ebcr.2018.07.004
359. RAJESH M., MUKHOPADHYAY P., BATKAI S., PATEL V., SAITO K., MATSUMOTO S., KASHIWAYA Y., HORVATH B., MUKHOPADHYAY B., BECKER L., HASKO G., ... MECHOULAM R. et al. : Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy, *Journal of the American College of Cardiology*, 2010, 56, (25), 2115-2125.
360. RAMER R., ROHDE A., MERKORD J., ROHDE H., HINZ B. : Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells, *Pharmacology Research*, 2010, 27, (10), 2162-2174.
361. RAMER R., MERKORD J., ROHDE H., HINZ B. : Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1, *Biochemical Pharmacology*, 2010, 79, (7), 955-966.
362. RAMER R., BUBLITZ K., FRIMUTH N., MERKORD J., ROHDE H., HAUSTEIN M., BORCHERT P., SCHMUHL E., LINNEBACHER M., HINZ B. : Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1, *The FASEB Journal*, 2012, 26, (4), 1535-1348.
363. RANGANATHAN M., de SOUZA D. et al. : Efficacy of Cannabidiol in the treatment of early psychosis, *Sixth Biennial SIRS Conference*, 2018.
364. REDDY D.S. : The Utility of Cannabidiol in the Treatment of Refractory Epilepsy, *Clin Pharmacol Ther*, 2017, 101, 2, 182-184.
365. REMISZEWSKI P., JAROCKA-KARPOWICZ I., BIERNACKI M., JASTRZAB A., SCHLICKER E., TOCZEK M., HARASIM-SYMBOR E., PEDZINSKA-BETIUK A., MALINOWSKA B. : Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats with Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism, *International Journal of Molecular Sciences*, 2020, 21, Art 1295, 1-24.
Doi : 10.3390/ijms21041295
366. REN Y., WHITTARD J. et al. : Cannabidiol, a non-psychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances, *Journal of Neuroscience*, 2009, 29, 47, 14764–14769.
367. RIBEIRO A., FERRAZ-de-PAULA V., PINHEIRO M.L., VITORETTI L.B., MARIANO-SOUZA D.P., QUINTEIRO-FILHO W.M., AKAMINE A.T., ALMEIDA V.I.,

- QUEVEDO J., DAL-PIZZOL F., HALLAK L.E., ZUARDI A.W., CRIPPA J.A., PALERMO-NETO J. : Cannabidiol, a non-psychotropic plant-derived cannabinoid decreases inflammation in a murine model of acute lung injury : role for the adenosine A(2A) receptor, *European Journal of Pharmacology*, 2012, 678, (1-3), 78-85.
368. ROBSON P. : Therapeutic aspects of cannabis and cannabinoids, *British Journal of Psychiatry*, 2001, 178, (2), 107-115.
369. ROBSON P.J., GUY G.W. : Metabolic abnormalities, abnormal stress response and chronic inflammation in schizophrenia - Potential Targets for Cannabinoid Medicine, *IACM Conference*, 2009.
370. ROCK E.M., LIMEBEER C.L., MECHOULAM R., PIOMELLI D., PARKER L.A. : The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat, *Psychopharmacology*, 2008, 196, 389-395.
371. ROCK E.M., BOLOGNINI D., LIMEBEER C.L., CASCIO M.G., ANAVI-GOFFNER S., FLETCHER P.J., MECHOULAM R., PERTWEE R.G., PARKER L.A. : Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behavior via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus, *British Journal of Pharmacology*, 2012, 165, (8), 2620-2634.
372. ROCK E.M., PARKER L.A. : Synergy between cannabidiol, cannabidiolic acid, and tetrahydrocannabinol in the regulation of emesis in the *Suncus murinus* (house musk shrew), *Behavioral Neuroscience*, 2015, 129, (3), 368-370.
373. ROCK E.M., PARKER L.A. : Cannabinoids as Potential Treatment for Chemotherapy-Induced Nausea and Vomiting, *Frontiers in Pharmacology*, 2016, 7, article 221.
Doi : 10.3389/fphar.2016.00221
374. ROHLEDER C., MÜLLER J.K., LANGE B., LEWEKE F.M. : Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence, *Frontiers in Pharmacology*, 2016, 7, 422, eCollection 2016
Doi : 10.3389/fphar.2016.00422
375. ROLLAND B., CHAPPUY M., CARRIERI P. : Le Cannabidiol, un agent thérapeutique prometteur ? *SWAPS*, 2019, 92-93, 5-6.
376. ROMANO B., BORRELLI F., PAGANO E., CASCIO M.G., PERTWEE R.G., IZZO A.A. : Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol, *Phytomedicine*, 2014, 21, (5), 631-639.
377. RONG C., CARMONA N.E., LEE Y.L., RAGGUETT R.-M., PAN Z., ROSENBLAT J.D. et al. : Drug-drug interactions as a result of coadministering Δ9-THC and CBD with other psychotropic agents, *Expert Opinion on Drug Safety*, 2018, 17, 1, 51-54.
Doi : 10.1080/14740338.2017.1397128
378. ROSENBERG E.C., TSIEN RW, WHALLEY B.J., DEVINSKY O. : Cannabinoids and Epilepsy, *Neurotherapeutics*, 2015, 18, 747-768. (Cochrane Review)
379. ROSENBERG E.C., LOUIK J., CONWAY E., DEVINSKY O., FRIEDMAN D. : Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol, *Epilepsia*, 2017, 1-5.
380. ROSER P., HAUSSLEITER I.S. : Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies, *Current Pharmaceutical Design*, 2012, 18, (32), 5141-5155.
381. ROSS H.R., NAPIER I., CONNOR M. : Inhibition of recombinant human T-type calcium channels by delta9-tetrahydrocannabinol and cannabidiol, *Journal of Biological Chemistry*, 2008, 283, 16124-16134.

382. RUBIN R. : Cannabidiol Products Are Everywhere, but Should People Be Using Them ?, *JAMA*, 2019, November 20, 1-3.
383. RUGGIERO R.N., ROSSIGNOLI M.T., De ROSS J.B., HALLAK J.E.C., LEITE J.P., BUENO-JUNIOR L.S. : Cannabinoids and Vanilloids in Schizophrenia : Neurophysiological Evidence and Directions for Basic Research, *Frontiers in Pharmacology*, 2017, 8, article 39927 pp.
Doi : 10.3389/fphar.2017.00399
384. RUIZ-VALDEPENAS L., MARTINEZ-ORGADO J.A., BENITO C., MILLAN A., TOLON R.M., ROMERO J. : Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain : an intravital microscopy study, *Journal of Neuroinflammation*, 2011, 8, (1), 5.
385. RUSSO E.B., BURNETT A., HALL B., PARKER K.K. : Agonistic properties of cannabidiol at 5-HT1A receptors, *Neurochemical Research*, 2005, 30, 1037-1043.
386. RUSSO E., GUY G.W. : A tale of two cannabinoids : the therapeutic rational for combining tetrahydrocannabinol and cannabidiol, *Medical Hypotheses*, 2006, 66, 2, 234-246.
387. RUSSO E.B. : Taming THC : potential cannabis synergy and phytocannabinoid-terpenoid entourage effects, *British Journal of Pharmacology*, 2011, 163, 7, 1344-1364.
Doi : 10.1111/j.1476-5381.2011.01238.x
388. RUSSO E.B. : Current therapeutic cannabis controversies and clinical trial design issues, *Frontiers in Pharmacology*, 2016, 7, 309.
389. RUSSO E.B. : Cannabis and epilepsy : An ancient treatment returns to the fore, *Epilepsy & Behavior*, 2016, 6 p.
390. RUSSO E.B. : Cannabidiol Claims and Misconceptions, *Trends on Pharmacological Sciences*, 2017, 38, 3, 198-201.
391. RUSSO E.B., MARCU J. : Cannabis pharmacology : the usual suspects and a few promising leads, *Adv Pharmacol*, 2017, 80, 71-138.
392. RYAN D., DRYSDALE A.J., LAFOURCADE C., PERTWEE R.G., PLATT B. : Cannabidiol targets mitochondria to regulate intracellular Ca²⁺ levels, *Journal of Neuroscience*, 2009, 29, (7), 2053-2063.
393. SAADE D., JOSHI C. : Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy : a case report, *Pediatric Neurology*, 2015, 52, 5, 544-547.
394. SAFT C., Von HEIN S.M., LÜCKE T., THIELS C. et al. : Cannabinoids for Treatment of Dystonia in Huntington's Disease, *Journal of Huntington's Disease*, 2018, 7, 2, 167-173.
395. SALERNO L., LIEBLICH S., McCANN J., TYLER J. : Is cannabis an effective treatment for anxiety disorders ?, *Anxiety.org*, September 03, 2019.
<https://www.anxiety.org/is-cannabis-an-effective-treatment-for-anxiety-what-research-shows>
396. SALES A.J., CRESTANI C.C., GUIMARAES F.S., JOCA S.R.L. : Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels, *Progress in Neuro-Psychopharmacology Biological Psychiatry*, 2018, 86, 255-261.
Doi : 10.1016/j.pnpbp.2018.06.002
397. SALES A.J., FOGACA M.V., SARTIM A.G., PEREIRA V.S., WEGENER G., GUIMARAES F.S., JOCA S.R.L. : Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex, *Molecular Neurobiology*, 2018, 12 p.

Doi : 10.1007/s12035-018-1143-4

398. SANTOS N.A., MARTINS N.M., SISTI F.M., FERNANDES L.S., FERREIRA R.S., QUEIROZ R.H., et al. : The neuroprotection of cannabidiol against MPP(+) -induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson's disease, *Toxicology In Vitro*, 2015, 30, (1 Pt B), 231-40.
399. SCHIER A.R. et al : Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug, *Psiquiatrica*, 2010, May, 32 Suppl 1, s104-110.
400. SCHIER A.R., RIBEIRO N.P., SILVA A.C., HALLAK J.E., CRIPPA J.A., NARDI A.E., ZUARDI A.W. : Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug, *Brazilian Journal of Psychiatry (Revista Brasileira de Psiquiatria)*, 2012, 34, suppl 1, 104-117.
401. SCHLEICHER E.M., OTT F.W., MÜLLER M. et al. : Prolonged cannabidiol treatment lacks on detrimental effects on memory, motor performance and anxiety in C57BL/6J mice, *Frontiers in Behavioral Neuroscience*, 2019, 13, 94.
Doi : 10.3389/fnbeh.2019.00094
402. SCHOEDEL K.A., HARRISON S.J. : Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols) : potentials and limitations for psychosis research, *Current Pharmaceutical Design*, 2012, 18, (32), 5008-5014.
403. SCHOEDEL K.A., SZETO I., SETNICK B., SELLERS E.M., LEVY-COOPERMAN N., MILLS C., ETGES T., SOMMERVILLE K. : Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial, *Epilepsy & Behavior*, 2018, 88, 162-171.
Doi : 10.1016/j.yebeh.2018.07.027
404. SCHONHOFEN P., BRISTOT I.J., CRIPPA J.A., HALLAK J.E.C., ZUARDI A.W., PARSONS R.B., KLAMT F. : Cannabinoid-Based Therapies and Brain Development : Potential Harmful of Early Modulation of the Endocannabinoid System, *CNS Drugs*, 2018, 1-16.
Doi : 10.1007/s40263-018-0550-4
405. SCHUBART C.D., SOMMER I.E.C., Van GASTEL W.A., GOETGEBUER R.L., KAHN R.S., BOKS M.P.M. : Cannabis with high cannabidiol content is associated with fewer psychotic experiences, *Schizophrenia Research*, 2011, 130, (1-3), 216-221.
406. SCHUBART C.D., SOMMER I.E.C., FUSAR-POLI P., De WITTE L., KAHN R.S., BOKS M.P.M. : Cannabidiol as a potential treatment for psychosis, *European Neuropsychopharmacology*, 2014, 24, 1, 51-64.
Doi : 10.1016/j.euroneuro.2013.11.002
407. SCHWARCZ G., KARAJGI B., McCARTHY R. : Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia, *Journal of Clinical Psychopharmacology*, 2009, 29, 3, 255-258.
408. SCHWARCZ G., KARAJGI B. : Improvement in refractory psychosis with dronabinol : four case reports, *Journal of Clinical Psychiatry*, 2010, 71, 11, 1552-1553.
409. SCOPINHO A.A., GUIMARAES F.S., CORREA F.M., RESSTEL L.B. : Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists, *Pharmacology Biochemistry and Behavior*, 2011, 98, (2), 268-272.
410. SCOTT K.A., SHAH S., DALGLEISH A.G., LIU W.M. : Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug

- combinations and treatment schedules, *Anticancer Research*, 2013, 33, (10), 4373-4380.
411. SCOTT K.A., DALGLEISH A.G., LIU W.M.: The combination of cannabidiol and delta-9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthoptic murine glioma model, *Molecular Cancer Therapeutics*, 2014, 13, (12), 2955-2967.
412. SCUDERY C. ET AL.: Cannabidiol in medicine : a review of its therapeutic potential in CNS disorders, *Phytotherapy Research*, 2009, 23, (5), 597-602.
Doi : 10.1002/ptr.2625
413. SEEMAN P.: Cannabidiol is a partial agonist at dopamine D2-High receptors, predicting its antipsychotic clinical dose, *Translational Psychiatry*, 2016, 6, e920.
Doi : 10.1038/tp.2016.195
414. SHALLCROSS J., HAMOR P., BECHARD A.R., ROMANO M., KNACKSTEDT L., SCHWENDT M.: The Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats, *Frontiers in Behavioral Neuroscience*, 2019, Vol 13, Article 91.
Doi : 10.3389/fnbeh.2019.00091
415. SHANNON S., OPILA-LEHMAN J.: Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder : A Case Report, *The Permanent Journal*, 2016, 20, 4, 108-111, PMID : 27768570.
416. SHANNON S.: Cannabidiol in the Treatment of Anxiety : A Large Case Series, Präsentiert am 21 April 2017 bei der *Psychodelic Science 2017, 19-24 April 2017*, San Francisco, USA.
417. SHANNON S., LEWIS N., LEE H., HUGHES S. : Cannabidiol in Anxiety and Sleep: A Large Case Series, *The Permanente Journal*, 2019, 23, 18-041. Doi : 10.7812/TPP/18-041
418. SHRIVASTAVA A., KUZONTKOSKI P.M., GROOPMAN J.E., PRASAD A. : Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy, *Molecular Cancer Therapeutics*, 2011, 10, (7), 1161-1172.
419. SOARES V.P., CAMPOS A.C.: Evidences for the Anti-panic Actions of Cannabidiol, *Current Neuropharmacology*, 2017, 15, 291-299.
Doi : 10.2174 / 1570159X14666160509123955
420. SOLINAS M., MASSI P., CINQUINA V., VALENTI M., BOLOGNINI D., GARIBOLDI M., MONTI E., RUBINO T., PAROLARO D.: Cannabidiol, a Non-Psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma cells Through a Multitarget Effect, *PLoS One*, 2013, 8, (10), e76918, 1-9.
421. SOLOWIJ N., BRODY S.J., Van HELL H.H., HAZEKAMP A. : A protocol for the delivery of cannabidiol (CBD) and combined CBD and Δ9-tetrahydrocannabinol (THC) by vaporisation, *BMC Pharmacology and Toxicology*, 2014, 15, 58.
Doi : 10.1186/2050-6511-15-58
422. SOLOWIJ N., BRODY S.J., BEALE C. et al : Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis users : A Pragmatic Open-Label Clinical Trial, *Cannabis and Cannabinoid Research*, 2018, 3, 1, 21-34.
423. SONEGO A.B., GOMES F.V., Del BEL E.A., GUIMARAES F.S. : Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the

- dorsolateral striatum via 5-HT1A receptors in mice, *Behavioural Brain Research*, 2016. doi : 10.1016/j.bbr.2016.04.042
424. SRIVASTAVA M.D., SRIVASTAVA BI., BROUHARD B. : Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells, *Immunopharmacology*, 1998, 40, 179-185.
425. STANLEY C.P., HIND W.H., O'SULLIVAN S.E. : Is the cardiovascular system a therapeutic target for cannabidiol ?, *British Journal of Clinical Pharmacology*, 2012, 75, (2), 313-322.
Doi : 10.1111/j.1365-2125.2012.04351.x
426. STANLEY C.P., HIND W.H. et al. : Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation, *Cardiovascular Research*, 2015, 107, 4, 568-578.
427. STRAIKER A., DVORAKOVA M., ZIMMOWITCH A., MACKIE K. : Cannabidiol inhibits endocannabinoid signaling in autaptic hippocampal neurons, *Molecular Pharmacology*, 2018, 97, (4), 20 p.
Doi : 10.1124/mol.118.111864
428. SZAFLARSKI J.P., BEBIN E.M. : Cannabis, cannabidiol and epilepsy – From receptors to clinical response, *Epilepsy & Behavior*, 2014, 41, 277-282.
429. SZAFLARSKI J.P., BEBIN E.M., COMI A.M., PATEL A.D. et al. : Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies : Expanded access program results, *Epilepsia*, 2018, 1-9.
430. SZAFLARSKI J.P., MARTINA BEBIN E., CUTTER G., DeWOLF J. et al. : Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study, *Epilepsy & Behavior*, 2018.
Doi : 10.1016/j.yebeh.2018.07.020.
431. SZAFLARSKI J.P. : Drug-drug interaction (DDI) studies with coadministration of cannabidiol (CBD) and clobazam (CLB), valproate (VPA), stiripentol (STP) or midazolam (MDZ) in healthy volunteers (HVTs) and adults with epilepsy, Presented at « 71st American Academy of Neurology Annual Meeting », May 4-10, 2019, Philadelphia, PA, S3.003.
432. TABITHA A.I., MATTIJS G.B. : A systematic review of the antipsychotic properties of cannabidiol in humans, *Schizophrenia Research*, 2015, 162, (1-3), 153-161.
433. TANG R., FANG F. : Trial of Cannabidiol for Drug -Resistant Seizures in the Dravet Syndrome, Comment, *New England Journal of Medicine*, 2017, 377, 7, 699.
434. THIELE E.A., MARSH E.D., FRENCH J.A. et al. – GWPCARE4 Study Group : Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4) : a randomised, double-blind, placebo-controlled phase 3 trial, *The Lancet*, 2018, 391, 1085-1096.
435. THIELE E.A., WONG M. : Cannabidiol (CBD) treatment in patients with seizures associated with tuberous sclerosis complex : a randomized, double-blind, placebo-controlled phase 3 trial (GWPCARE6), Presented at « American Epilepsy Society meeting 2019 », December 6-10, 2019, Baltimore, Maryland, Abstract 1.293.
436. THOMAS A., BAILLIE G.L., PHILLIPS A.M., et al. : Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro, *British Journal of Pharmacology*, 2007, 150, 613-623.
Doi : 10.1038/sj.bjp.0707133

437. TREMBLY B., SHERMAN M. : Double -blind clinical study of cannabidiol as a secondary anticonvulsant, in « *Marijuana'90 International Conference on Cannabis and Cannabinoids* », 1990.
438. TRINGALE R., JENSEN C. : Cannabis and insomnia, *Depression*, 2011, 4, (12), 0-68.
439. TURKANIS S.A., SMILEY K.A., BORYS H.K., OLSEN D.M., KARLER R. : An electrophysiological analysis of the anticonvulsant action of cannabidiol on limbic seizures in conscious rats, *Epilepsia*, 1979, 20, 4, 351-363.
440. TURNA J., SYAN S.K., FREY B.N., RUSH B., COSTELLO M.J., WEISS M., MCKILLOP J. : Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy : A Systematic Review, *Alcoholism : Clinical and Experimental Research*, 2019, 1-14.
441. TURNER A.L. : Cannabis, Cannabidiol, and Epilepsy. Clinical Considerations and Practical Applications, *Practical Neurology*, 2018, 31-35
442. TZADOK M., ULIEL-SIBONI S., LINDER I. et al. : CBD-enriched medical cannabis for intractable pediatric epilepsy : the current Israeli experience, *Seizure*, 2016, 35, 41-44.
443. UJVARY I., HANUS L. : Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy, *Cannabis & Cannabinoid Research*, 2016, 1, 90-101.
444. UPADHYA D., CASTRO O.W., UPADHYA R., SHETTY A.K. : Prospects of cannabidiol for easing Status Epilepticus-Induced Epileptogenesis and related Comorbidities, *Molecular Neurobiology*, 25 January 2018.
Doi : 10.1007/s12035-018-0898-y
445. US Food and Drug Administration : What you need to know (and what we're working to find out) about products containing cannabis or cannabis-derived compounds, including CBD, November 25, 2019.
Available at : <https://www.fda.gov/consumers/consumer-updates/what-you-need-know-and-what-were-working-find-out-about-products-containing-cannabis-or-cannabis>
446. VALVASSORI S.S., ELIAS G., de SOUZA B., PETRONILHO F., DAL-PIZZOL F., KAPCZINSKI F., TRZESNIAK C., TUMAS V., DURSUN S., CHAGAS M.H., HALLAK J.E., ZUARDI A.W., QUEVEDO J., CRIPPA J.A. : Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania, *Journal of Psychopharmacology*, 2009.
PMID : 19939866
447. VALVASSORI S.S., BAVARESCO D.V., SCAINI G., VARELA R.B., STREK E.L., CHAGAS M.H., HALLAK J.E.C., ZUARDI A.W., CRIPPA J.A., QUEVEDO J. : acute and Chronic administration of cannabidiol increases mitochondrial complex and creatinine kinase activity in the rat brain, *Revista Brasileira de Psiquiatria*, 2013, 35, 380-386.
Doi : 10.1590/1516-4446-2012-0886
448. VANDREY R., RABER J.C., RABER M.E. : Cannabinoid dose and label accuracy in edible medical cannabis products, *JAMA*, 2015, 313, 2491-2493.
449. Van KLINGEREN B., TEN HAM M. : Antibacterial activity of delta9-tetrahydrocannabinol and cannabidiol, *Antonie van Leeuwenhoek*, 1976, 42 (1-2), 9-12.

450. VANN R.E., GAMAGE T.F., WARNER J.A. et al. : Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ9-tetrahydrocannabinol, *Drug and Alcohol Dependence*, 2008.
- Doi : 10.1016/j.drugalcdep.2007.11.017
451. VILELA L.R., GOMIDES L.F., DAVID B.A., ANTUNES M.M., DINIZ A.B., de ARAUJO MOREIRA F., MENEZES G.B. : Cannabidiol rescue Acute Hepatic Toxicity and Seizure Induced by Cocaine, *Mediators of Inflammation*, Hindawi Publishing Corporation, 2015, Art 523418, 12 p.
- Doi : 10.1155/2015/523418
452. VIUDEZ-MARTINEZ A., GARCIA-GUTIERREZ M.S., MANZANARES J. : Gender differences in the effects of cannabidiol on ethanol binge drinking in mice, *Addiction Biology*, 2019, e12765.
- Doi : 10.1111/adb.12765
453. VOLKOW N.D. : The biology and potential therapeutic effects of cannabidiol, *National Institute on Drug Abuse, Senate Caucus on International Narcotics Control*, June 24, 2015.
454. WAKEFORD A.G.P., WETZELL B.B., POMFREY R.L., CLASEN M.M., TAYLOR W.W., HEMPEL B.J., RILEY A.L. : The effects of cannabidiol (CBD) on Δ⁹-tetrahydrocannabinol (THC) self-administration in male and female Long-Evans rats, *Experimental and Clinical Psychopharmacology*, 2017, 25, (4), 242-248.
- Doi : 10.1037/phc0000135
455. WALL M.B., POPE R., FREEMAN T.P., KOWALCZYK O.S., DEMETRIOU L., MOKRYSZ C., HINDOCHA C., LAWN W., BLOOMFIELD A.P., FREEMANA.M., FEILDING A., NUTT D.J., CURRAN H.V. : Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity, *Journal of Psychopharmacology*, 2019, 1-9.
- Doi : 10.1177/0269881119841568
456. WALSH Z., GONZALES R., CROSBY K., THIESSEN M.S., CARROLL C., BONN-MILLER M.O. : Medical cannabis and mental health : a guided systematic review, *Clinical Psychological Review*, 2017, 51, 15-29.
- Doi : 10.1016/j.cpr.2016.10.002
457. WELTY et al. : Cannabidiol : promise and pitfalls, *Epilepsy Currents*, 2014, 14, 5, 250-252.
458. WHELESS J.W., DLUGOS D., MILLER I., OH D.A., PARIKH N., PHILLIPS S., RENFROE J.B., ROBERTS C.M., SAEED I., SPARAGANA S.P., YU J., CILIO M.R., on behalf of the INS011-14-029 Study Investigators, *CNS Drugs*, 2019, 1-12.
- Doi : 10.1007/s40263-019-00624-4
459. WHITE C.M. : A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential, *The Journal of Clinical Pharmacology*, 2019, 59, (7), 923-934.
- Doi : 10.1002/jcph.1387
460. WHO : CANNABIDIOL (CBD), Pre-Review Report, Agenda Item 5.2, Expert Committee on Drug Dependence, Thirty-ninth Meeting, Geneva, 6-10 November 2017, 39th ECDD (2017).
461. WINTON-BROWN T.T., ALLEN P., BHATTACHARYYA S. et al. : Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study, *Neuropsychopharmacology*, 2011, 36, 1340-1348.

462. WRIGHT M.J., VANDERWATER S.A., TAFFE M.A. : Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ9-Tetrahydrocannabinol, *British Journal of Pharmacology*, 2013, 170, 1365-1373.
Doi : 10.1111/bph.12199
463. WRIGHT M., Di CIANO P., BRANDS B. : Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence, Cannabis and Cannabinoid research, 2020.
Doi 10.1089/can.2019.0052
464. WU H.Y., CHU R.M., WANG C.C., LEE C.Y., LIN S.H., JAN T.R. : Cannabidiol-induced apoptosis in primary lymphocytes is associated with oxidative stress-dependent activation of caspase-8, *Toxicology and Applied Pharmacology*, 2008, 226, (3), 260-270.
Doi : 10.1016/j.taap.2007.09.012
465. XU C., CHANG T., DU Y., YU C., TAN X., LI X. : Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model, *Environmental Toxicology and Pharmacology*, 2019, 30, 70, 103202
Doi : 10.1016/j.etap.2019.103202
466. YANG K.-H., GALADARI S., ISAEV D., PETROIANU G., SHIPPENBERG T.S., OZ M. : The Nonpsychoactive Cannabinoid Cannabidiol Inhibits 5-Hydroxytryptamine_{3A} Receptor-Mediated Currents in *Xenopus laevis* Oocytes, *Journal of Pharmacology and Experimental Therapeutics*, 2010, 333, (2), 547-554;
Doi : 10.1124/jpet.109.162594
467. YANG L., ROZENFELD R., WU D., DEVI L., ZHANG Z., CEDERBAUM A. : Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy, *Free Radical Biology & Medicine*, 2014, 68, 260-267.
Doi : 10.1016/j.freeradbiomed.2013.12.026
468. YASGUR B.S., BARCLAY L. : Cannabidiol in Patients with Clinical High Risk Psychosis, 18/10/2018.
<http://www.medscape.org/viewarticle/902628>
469. YASGUR B.S. : Canabidiol May Reset Brain Function in Psychosis, *Medscape Psychiatry News*, 2018 Sept 04.
https://www.medscape.com/viewarticle/901533_print
470. ZANELATI T.V., BIOJONE C., MOREIRA F.A., GUIMARAES F.S., JOCA S.R. : Antidepressant-like effects of cannabidiol in mice : possible involvement of 5-HT1A receptors, *British Journal of Pharmacology*, 2010, 159, 1, 122-128.
Doi : 10.1111/j.1476-5381.2009.00521.x
471. ZUARDI A.W., SHIRAKAWA I., FINKELFARB E., KARNIOL I.G. : Action of cannabidiol on the anxiety and other effects produced by δ⁹-THC in normal subjects, *Psychopharmacology (Berl)*, 1982, 76, 3, 245-250.
472. ZUARDI A.W., TEIXEIRA N.A., KARNIOL I.C. : Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats, *Archives Internationales de Pharmacodynamie et de Therapie*, 1984, 269, (1), 12-19.
473. ZUARDI A.W. et al. : Effects of cannabidiol in animal models predictive of antipsychotic activity, *Psychopharmacology*, 1991, 104, 2, 260-264.
474. ZUARDI A.W., COSME R.A., GRAEFF F.G., GUIMARÃES F.S. : Effects of ipsapirone and cannabidiol on human experimental anxiety. *J Psychopharmacol*. 1993, 7, 82-88.

475. ZUARDI A.W., MORAIS S.L., GUIMARÃES F.S., MECHOULAM R.: Antipsychotic effects of cannabidiol, *Journal of Clinical Psychiatry*, 1995, 56, 10, 485-486.
476. ZUARDI A.W., GUIMARÃES F.S.: Cannabidiol as an anxiolytic and antipsychotic, in *Mathre ML (Editor), Cannabis in Medical Practice.*, McFarland & Company, Inc., Jefferson, NC, USA, 1997, 133-141.
477. ZUARDI A.W., CRIPPA J.A.S., HALLAK J.E.C., MOREIRA F.A., GUIMARÃES F.S.: Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug, *Brazilian Journal of Medical and Biological Research*, 2006, 39, (4), 421-429.
478. ZUARDI A.W., HALLAK J.E.C., DURSUN S.M., MORAIS S., SANCHES R.F., MUSTY R.E., CRIPPA J.A.S.: Cannabidiol monotherapy for treatment-resistant schizophrenia, *Journal of Psychopharmacology*, 2006, 20, 5, 683-686.
<https://fr.scribd.com/document/77189626/Antonio-Waldo-Zuardi-et-al-Cannabidiol-monotherapy-for-treatment-resistant-schizophrenia>
479. ZUARDI A.W.: History of cannabis as a medicine: a review, *Revista Brasileira Psiquiatrica*, 2006, 28, (2), 153-157.
480. ZUARDI A.W.: Cannabidiol : From an inactive cannabinoid to a drug with wide spectrum of action, *Revista Brasileira Psiquiatrica*, 2008, 30, 271-280.
481. ZUARDI A.W., CRIPPA J.A.S., HALLAK J.E.C., PINTO J.P., CHAGAS M.H.N., RODRIGUES G.G.R. et al. : Cannabidiol for the treatment of psychosis in Parkinson's disease, *Journal of Psychopharmacology*, 2009, 23, 8, 979-983.
482. ZUARDI A.W., CRIPPA J.A.S., DURSUN S.M., MORAIS S., VILELA J.A.A., SANCHES R.F., HALLAK J.E.C. : Cannabidiol was ineffective for maniac episod of bipolar affective disorder, *Journal of Psychopharmacology*, 2010, 24, 1, 135-137.
483. ZUARDI A.W., CRIPPA J.A. et al. : A critical review of the Antipsychotic Effects of Cannabidiol : 30 Years of a translational Investigation, *Current Pharmaceutical Design*, 2012, 18, 5131-5140.
484. ZUARDI A.W., de SOUZA CRIPPA J.A., HALLACK J.A. et al. : The Anxiolytic Effects of Cannabidiol (CBD), December 2017.
485. ZUARDI A.W., RODRIGUES N.P., SILVA A.L., BERNARDO S.A., HALLAK J.E.C., GUIMARAES F.S., CRIPPA J.A.S. : Inverted U-Shape Dose-Reponse Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life, *Frontiers in Pharmacology*, 2017.
- Doi : 10.3389/fphar.2017.00269

WHO : CANNABIDIOL (CBD), Pre-Review Report, Agenda Item 5.2, Expert Committee on Drug Dependence, Thirty-ninth Meeting, Geneva, 6-10 November 2017, 39th ECDD (2017)